A Phase I Dose Escalation Study of Harmine in Healthy Subjects
PI: James Murrough, MD, PhD
[STUDY_ID_REMOVED]
Document Date: June 6, 2023
Protocol STUDY-20-01329 Confidential
Page 1 of 43Icahn School of Medicine at 
Mount Sinai
Clinical Research Protocol 
Phase 1 Dose Escalation Study of 
Harmine in Healthy Adults
Protocol Number: STUDY-20-01329
Version Date: 01.24.2023
Investigational Product: Harmine
IND Number: 148461
Development Phase: Phase 1
Funding Organization: 
NIHNational Institute of Diabetes and Digestive and Kidney 
Diseases/NIH/DHHS
Principal Investigator: Name: James Murrough 
Telephone: 212-585-4640
Fax: 212-241-3354
E-mail: james.murrough@mssm.edu
Effective Date: 6/6/2023
End Date:6/5/2024

Protocol STUDY-20-01329 Confidential
Page 2 of 43Table of Contents
LIST OF ABBREVIATIONS ........................................................................................................................4
PROTOCOL SYNOPSIS ...............................................................................................................................5
1 BACKGROUND ...............................................................................................................................12
2 STUDY RATIONALE ......................................................................................................................15
2.1 Facilities and Resources ...................................................................................................................16
2.2 Risk / Benefit Assessment .................................................................................................................19
Risks to Subjects: ........................................................................................................................................19
2.3 Recruitment Methods ........................................................................................................................20
3 STUDY OBJECTIVES .....................................................................................................................21
3.1 Primary Objective .............................................................................................................................21
3.2 Secondary Objectives ........................................................................................................................21
4 STUDY DESIGN ..............................................................................................................................21
4.1 Study Overview .................................................................................................................................21
5 CRITERIA FOR EVALUATION ......................................................................................................25
5.1 Primary Endpoint .............................................................................................................................25
5.2 Secondary Endpoints ........................................................................................................................25
5.3 Safety Evaluations ............................................................................................................................25
5.4 Other Evaluations .............................................................................................................................25
6 SUBJECT SELECTION ...................................................................................................................25
6.1 Study Population ..............................................................................................................................25
6.2 Inclusion Criteria .............................................................................................................................25
6.3 Exclusion Criteria ............................................................................................................................26
7 CONCURRENT MEDICATIONS ....................................................................................................27
7.1 Allowed Medications and Treatments ...............................................................................................27
7.2 Prohibited Medications and Treatments ............................................................................................27
8 STUDY PROCEDURES AND GUIDELINES ..................................................................................27
8.1 Clinical Assessments .........................................................................................................................27
8.1.1 Diagnostic Assessment ......................................................................................................................27
8.1.2 Self-Report Questionnaires ...............................................................................................................27
8.1.3 Concomitant Medications .................................................................................................................27
Effective Date: 6/6/2023
End Date:6/5/2024

Protocol STUDY-20-01329 Confidential
Page 3 of 438.1.4 Demographics ..................................................................................................................................27
8.1.5 Medical History ................................................................................................................................27
8.1.6 Adverse Events .................................................................................................................................27
8.1.7 Urine Toxicology Test (UTOX) .........................................................................................................27
8.1.8 Pregnancy Test .................................................................................................................................27
8.1.9 Urinalysis .........................................................................................................................................27
9 EVALUATIONS BY VISIT ..............................................................................................................28
9.2 Treatment Visit (V1) .........................................................................................................................29
Refer to Table 2 for Visit 1 procedures. .......................................................................................................29
9.3 Follow-up/Study Exit (V2) ................................................................................................................29
10 ADVERSE EXPERIENCE REPORTING AND DOCUMENTATION ..............................................33
10.1 Adverse Events .................................................................................................................................33
AE Severity .................................................................................................................................................33
AE Relationship to Study Drug ...................................................................................................................33
10.2 Serious Adverse Experiences (SAE) ..................................................................................................34
AE/SAE Reporting Procedure To Mount Sinai PPHS (IRB) ........................................................................34
11 DISCONTINUATION AND REPLACEMENT OF SUBJECTS .......................................................35
12 Withdrawal of Subjects from the Study .............................................................................................35
13 PROTOCOL VIOLATIONS ..............................................................................................................35
14 DATA SAFETY MONITORING ......................................................................................................36
15 STATISTICAL METHODS AND CONSIDERATIONS ...................................................................37
16 DATA COLLECTION, RETENTION AND MONITORING ............................................................38
16.1 Data Collection Instruments .............................................................................................................38
16.2 Data Management Procedures ..........................................................................................................39
16.3 Data Quality Control and Reporting .................................................................................................39
16.4 Archiving of Data .............................................................................................................................39
16.5 Availability and Retention of Investigational Records .......................................................................40
16.6 Subject Confidentiality .....................................................................................................................40
17 ADMINISTRATIVE, ETHICAL, REGULATORY CONSIDERATIONS ..........................................40
17.1 Protocol Amendments .......................................................................................................................40
17.2 Institutional Review Boards and Independent Ethics Committees .....................................................41
Effective Date: 6/6/2023
End Date:6/5/2024

Protocol STUDY-20-01329 Confidential
Page 4 of 4317.3 Informed Consent Form ...................................................................................................................41
17.4 Publications ......................................................................................................................................42
17.5 Investigator Responsibilities .............................................................................................................42
APPENDIX 1. SCHEDULE OF STUDY VISITS ........................................................................................43
LIST OF ABBREVIATIONS
AE Adverse Event
CFR Code of Federal Regulations
CRF Case Report Form
DAC Depression and Anxiety Center
DMC Data Monitoring Committee
DSMB Data Safety Monitoring Board
FDA Food and Drug Administration
GCP Good Clinical Practice
HIPAA Health Insurance Portability and Accountability Act of 1996
ICF Informed Consent Form
ICH International Conference on Harmonization
IEC Independent Ethics Committee
IRB Institutional Review Board
ISMMS Icahn School of Medicine at Mount Sinai
MINI Mini International Neuropsychiatric Interview
PI Principal Investigator
PPHS Program for the Protection of Human Subjects
SAE Serious Adverse Event
SCID-5 Structured Clinical Interview for DSM-5 Disorders
Effective Date: 6/6/2023
End Date:6/5/2024

Protocol STUDY-20-01329 Confidential
Page 5 of 43PROTOCOL SYNOPSIS
TITLE Phase 1 Dose Escalation of Harmine in Healthy Adults
FUNDING 
ORGANIZATIO
NNational Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
NUMBER OF SITES 1
RATIONALEThe present study is an open label phase 1 dose escalation study in healthy 
volunteers. The primary goals of the trial are to determine the maximum 
tolerated dose of harmine as well as to characterize the psychoactive effects of 
the drug. A continual reassessment model with 7 doses of harmine at 100 mg, 
200 mg, 300 mg, 500 mg, 700 mg, 900 mg, and 1200 mg will be utilized in 
order to monitor and determine the tolerability of the drug. The results of the 
study will inform future trials in regard to the safety and efficacy of harmine, 
which is thought to be an alternative medication for diabetes. The present study 
is a jump-off point for the next phases of treatment development. 
Regenerating insulin-producing beta-cells could potentially free millions of 
diabetes patients from daily doses of insulin, and thus, remains an important 
objective in developing treatments for diabetes. Loss of insulin-producing beta 
cells has long been recognized as a cause of type 1 diabetes and has recently 
been identified as an important contributor to type 2 diabetes as well. Though 
there have been efforts in producing a therapy to increase the number of 
functional beta cells in patients, the major obstacle has been identifying an 
agent that does so by a degree that is actually therapeutic.
Recently, a harmala alkaloid called harmine has demonstrated promise to be an 
effective therapy for both type 1 and type 2 diabetes. In-vivo and in-vitro 
studies have shown harmine to robustly induce beta cell proliferation at rates 
that may have treatment implications. Further specificity studies identified dual 
specificity tyrosine-regulated kinase-1a (DYRK1A) as the likely target for 
harmine. Harmine occupied the ATP pocket of DYRK1A, leading to its 
inhibition and, ultimately, to beta cell expansion (Wang 2015). Given that 
harmine‚Äôs therapeutic application for diabetes has never been studied in 
humans, we propose a phase 1 study of harmine to pioneer clinical research 
efforts of this potential new therapy.
Harmine is consumed as part of Ayahuasca which is a hallucinogenic brew 
made from B. cappi bark and leaves of Psychotria viridis [which contain N,N-
dimethyltryptamine (DMT)], and used recreationally by Amazonian tribes and 
has been studied recently for its potential psychotropic effects. Harmine in 
ayahuasca inhibits the breakdown of DMT and elevates its levels in systemic 
circulation in brain reversible inhibition of monoamine oxidase (MAO) A 
(MAO-A) enzyme. The hallucinogenic effects of ayahuasca are attributed to 
DMT, a 5-HT1A/2A/2C agonist.
Research Question: This study is designed to investigate the safety of oral 
administration of harmine using an open label, two-stage, continual 
Effective Date: 6/6/2023
End Date:6/5/2024

Protocol STUDY-20-01329 Confidential
Page 6 of 43reassessment method with 7 doses of harmine at 100mg, 200mg, 300mg, 
500mg, 700mg, 900mg and 1200mg in healthy volunteers. We anticipate that 
the proposed study will yield the maximum tolerated dose (MTD) for harmine, 
which will guide future research efforts toward novel diabetes treatments.
STUDY DESIGN This is Phase 1 dose escalation study.
PRIMARY OBJECTIVE The principal goal of our clinical trial is to establish the Maximum Tolerated 
Dose (MTD) of harmine in healthy patients that will inform the recommended 
phase II dose. 
Hypothesis: Orally administered harmine will be well-tolerated with minimal 
dose-limiting toxicities at our testing doses.
SECONDARY 
OBJECTIVESCharacterize psychoactive effects of harmine in healthy adults.
Hypothesis: Orally administered harmine will be well-tolerated and will not induce 
burdensome psychoactive effects in healthy adults.
NUMBER OF 
SUBJECTSN=40 patients dosed; N=54 anticipated screening
SUBJECT 
SELECTION 
CRITERIAInclusion Criteria
‚Ä¢ Male or female aged 18-55 years;
‚Ä¢Rationale: We wish to exclude children under the age of 18 and adults over the 
age of 55 in part due to concerns regarding neurodevelopmental and 
neurocognitive effects, respectively.
‚Ä¢ Participants must have a level of understanding of the English language sufficient 
to agree to all tests and examinations required by the study and must be able to 
participate fully in the informed consent process;
‚Ä¢ Body Mass Index (BMI) between 19 and 30;
‚Ä¢Rationale: We wish to exclude individuals who are underweight as defined as a 
BMI <19, or who are obese as defined as >30 according to the Centers for 
Disease Control (CDC). These criteria are in line with the goals of a phase I dose 
finding and pharmacokinetic study.
‚Ä¢ Women of childbearing potential and men must be using an acceptable method of 
contraception to avoid pregnancy throughout the study as judged by the 
investigator;
‚Ä¢ Women must not be breastfeeding;
Exclusion Criteria
‚Ä¢ Presence of a significant medical illness i.e., delirium, metastatic cancer, 
decompensated cardiac, liver or kidney failure, major surgery, stroke or 
myocardial infarction during the three months prior to entry;
‚Ä¢ Presence of a significant neurological disease such as Parkinson's disease, primary 
or secondary seizure disorders, intracranial tumors, severe head trauma; 
neurodegenerative diseases;
‚Ä¢ Presence of neurocognitive or dementing disorders;
‚Ä¢ Presence or history of psychiatric disorder as diagnosed by Mini Neuropsychiatric 
Interview (MINI);
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 7 of 43Protocol STUDY-20-01329
‚Ä¢ Urine toxicology positive for illicit drugs or dis-allowed concomitant medications 
as per study protocol;
‚Ä¢ Medications with primary central nervous system (CNS) effects are dis-allowed, 
including psychotropic medications, antidepressants, benzodiazepines, centrally 
acting hypnotic agents, and centrally acting anti-migraine therapies;
‚Ä¢ Medications with primary cardiovascular effects are dis-allowed, including beta-
adrenergic antagonists, ACE inhibitors, calcium channel blockers, and diuretics;
‚Ä¢ Any OTC medications or herbal remedies that could interfere with the study drug, 
pose a risk to the subject, or contain high tyramine as outline in the Low Tyramine 
Diet attachment;
‚Ä¢ Any other medications that, in the opinion of the investigators, would pose a 
safety risk to the patient or that would interfere with the interpretation of study 
results;
‚Ä¢ Positive pregnancy test at screen or on the morning of the treatment day in women 
of childbearing potential;
‚Ä¢ Systolic blood pressure outside the range of 100 - 140 mmHg, diastolic blood 
pressure outside the range of 60 - 90 mmHg, and pulse rate at rest > 100 or < 60 
bpm;
‚Ä¢ History of positive tests for hepatitis B surface antigen, hepatitis C antibodies;
‚Ä¢ History of HIV;
‚Ä¢ Significant ECG abnormalities as follows:
‚Ä¢ Heart Rate < 60 and >100 bpm
‚Ä¢ PR Interval <120 and > 220 ms
‚Ä¢ QRS duration < 70 and >120 ms
‚Ä¢ QTC Interval (Bazett) > 450 ms
TEST PRODUCT, 
DOSE, AND ROUTE 
OF 
ADMINISTRATIONHarmine will be administered orally at 100mg, 200mg, 300mg, 500mg, 
700mg, 900mg and 1200mg. 
The drug will be manufactured at the University of Minnesota College of 
Pharmacy Institute for Therapeutics Discovery and Development.
CONTROL 
PRODUCT, DOSE 
AND ROUTE OF 
ADMINISTRATIONN/A
4 OF SUBJECT 
PARTICIPATION 
AND DURATION OF 
STUDYWe expect that for each subject, the study will last up to 8 weeks from 
recruitment to completion of all study procedures. Data analyses will be 
finished in up to 3 months after all the samples are collected.
CONCOMMITAN
T  MEDICATIONSAll of the following medications are prohibited:
Hypertension Drugs:
Ace inhibitors: enalapril (Vasotec, Epaned), lisinopril (Prinivil, 
Zestril, Qbrelis), and ramipril (Altace
Angiotensin II receptor blockers (ARBs): valsartan (Diovan), 
losartan (Cozaar)
Calcium channel blockers: amlodipine (Norvasc), diltiazem 
(Cardizem, Tiazac, others), nifedipine (Adalat CC, Procardia), and 
verapamil (Verelan, Calan)
Beta-Blockers: metoprolol (Lopressor, Toprol-XL), nadolol 
(Corgard), and atenolol (Tenormin)
Reni inhibitors: Aliskiren (Tekturna)
Diuretics: chlorothiazide (Diuril), bumetanide (Bumex), and 
amiloride (Midamor)
Alpha-blockers: doxazosin (Cardura), prazosin (Minipress), and 
terazosin.
Alpha-beta blockers: carvedilol (Coreg) and labetalol.
Central-acting agents: clonidine (Catapres, Kapvay), guanfacine 
(Intuniv), and methyldopa.
Vasodilators: hydralazine and minoxidil.
Aldosterone antagonists: spironolactone (Aldactone, Carospir) and 
eplerenone (Inspra)
Any medication with central nervous system activity: 
Antidepressants: SSRIs, SNRIs, Atypical Antidepressants, TCAs
Barbiturates: mephobarbital (Mebaral) and pentobarbital sodium 
(Nembutal)
Benzodiazepines: diazepam (Valium), chlordiazepoxide HCl 
(Librium), and alprazolam (Xanax)
Stimulants: amphetamine (Adderall, Dexedrine, Dyanavel, Evekeo, 
ProCentra, Vyvanse), methamphetamine (Desoxyn), 
methylphenidate (Aptensio, Metadate, Concerta, Daytrana, Ritalin, 
Methylin, QuilliChew, Quillivant)
Mood stabilizers: Carbamazepine (Carbatrol, Epitol, Equetro, 
Tegretol), Divalproex sodium (Depakote), Lamotrigine (Lamictal), 
Lithium, Valproic acid (Depakene)
Antipsychotics: aripiprazole (Abilify), asenapine (Saphris), 
cariprazine (Vraylar), clozapine (Clozaril), lurasidone (Latuda), 
olanzapine (Zyprexa), quetiapine (Seroquel), risperidone 
(Risperdal), ziprasidone (Geodon)
Herbal:
The following herbal medicines should not be combined with 
ayahuasca and must be stopped at least two weeks prior to study.
St. Johns Wort 
Kava
Kratom
Ephedra
Ginseng
Yohimbe
Sinicuichi
Rhodiola Rosea
Kanna
Boswellia
Nutmeg
Scotch Broom
Licorice Root
Cannabis
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 8 of 43Protocol STUDY-20-01329
EFFICACY 
EVALUATION
SEfficacy will be the main focus of future Phase II and III studies. The current 
protocol is focused on safety, which will better inform future efficacy 
studies.
PRIMARY 
ENDPOINTThe primary endpoint of our clinical trial is to establish the Maximum 
Tolerated Dose (MTD) of harmine in healthy patients in a phase I dose 
escalation study for efficacy testing in phase II trials. See above for MTD and 
DLT definitions where safety is the primary endpoint.
SECONDAR
Y 
ENDPOINTSA secondary endpoint is to characterize psychiatric effects of orally 
administered harmine in healthy adults.
OTHER 
EVALUATION
SN/A
SAFETY 
EVALUATION
S‚Ä¢ Psychosis / mental status changes: BPRS, other clinical scales
‚Ä¢ PRISE: nausea, vomiting, diarrhea and other general adverse events
‚Ä¢ Vitals: BP, HR, Temp, Respiration
‚Ä¢ Unanticipated effects: spontaneous reporting and structured assessment 
with the PRISE
STATISTICS
Primary Analysis 
PlanHuman data on oral harmine administration are limited and of poor quality, 
as noted above. Briefly, there is only one study that employed oral doses in 
the range of 20 to 960 mg (Pennes et al., 1957). No subject had any adverse 
visual hallucinations. Some subjects (number uncertain) experienced 
‚Äúnausea, vomiting, slow coarse spontaneous tremor, ‚Äòwaviness‚Äô of the 
environment, ‚Äòsinking‚Äô sensations of the body, subjective sense of body 
vibration, and subject numbness accompanied by reduced sensitivity to light 
touch and pinprick‚Äù. These effects were apparently observed only in ‚Äúsome 
subjects‚Äù and only ‚Äúoccurred with oral doses higher than the threshold of 
300.0-400.0 mg.‚Äù In addition, the Callaway Ayahuasca study (Callaway et 
al., 1999) administered harmine in the Ayahuasca ‚Äútea‚Äù at the dose of 3.4 
mg/kg (range 204-306 mg). Callaway et al. noted that the effects of this dose 
of harmine (along with other ingredients of Ayahuasca) was perceived to be 
mild. Thus, based on this limited data, doses below 200 mg are likely safe, 
and single oral doses as high as 1000 mg may also be safe and free of 
significant adverse effects For this reason, and an added layer of caution, we 
have elected to initiate dosing at 100 mg which is less than half of the lower 
dose range in Callaway study. The upper level of dose range (1200 mg) is 4-
times that of the highest dose of Callaway study.
In terms of selecting the number of doses tested between the established 
minimum (100 mg) and maximum (1200 mg) dose, the most important 
statistical consideration is whether the doses and dose range under 
investigation are likely to allow an accurate MTD estimate. In general, it is 
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 9 of 43Protocol STUDY-20-01329
recommended that phase I studies contain between 2 and 12 dosing levels 
(Penel and Kramar, 2013); more levels generally allow for a more accurate 
determination of the MTD. Based primarily on clinical data, together with the 
available pre-clinical safety data, and utilizing established methods for 
defining the incremental sequence of a range of doses (Le Tourneau et al., 
2009), our study protocol specifies the following 7 oral harmine dose levels 
to be tested according to the dose escalation model described below: 100 mg, 
200 mg, 300 mg, 500 mg, 700 mg, 900 mg and 1200 mg.
Our study will employ the continual reassessment method (CRM) to find the 
MTD of harmine (O'Quigley 1990). Generally, the CRM starts by selecting a 
target dose-limiting toxicity rate and a mathematical model assumed to 
govern the relationship between dose and toxicity; the prior dose-toxicity 
curve. After outcomes are observed (i.e., a patient experiences a DLT or not), 
the dose-toxicity curve is refit incorporating the latest outcome. The next 
dose assigned is that which is most likely to be associated with the target 
toxicity level (the MTD). At every step, the next patient is assigned the dose 
estimated to be nearest to the MTD. While the ‚Äú3 + 3‚Äù design is the most 
commonly employed dose finding design, the CRM is generally accepted by 
statisticians as superior due to two main advantages: (1) the CRM provides a 
mechanism for stopping at a specified toxicity level, whereas the targeted 
toxicity rate for the MTD from the ‚Äú3 + 3‚Äù design is necessarily in the range 
of 16%-33%, and (2) the CRM is more efficient; it can establish the MTD 
more accurately and precisely from fewer patients and it minimizes the 
number of patients treated at unsafe doses. The CRM is a model-based design 
while that of the 3+3 is a rule-based design.
Our implementation of the CRM is a Bayesian model-based method that will 
employ a logistic one-parameter prior for the model parameter Œ±. We have 
chosen this model for two principal reasons; its simplicity and efficiency. 
Generally, the one-parameter model is more efficient than two parameter 
models. That is, it requires fewer patients to precisely estimate that aspect of 
the dose-toxicity curve that is allowed to vary (the slope or steepness 
parameter). This increased efficiency in parameter estimation may come at 
the cost of a slight decrease in the accuracy of depicting the entire dose-
toxicity relationship. However, the CRM has proven to be robust in choosing 
an MTD, even if the functional form is moderately incorrect. In large part 
this robustness is due to the fact that the CRM is not concerned with 
accurately estimating all aspects of the dose-toxicity curve, but rather the area 
near the location of the MTD. The Inputs to specify for our model are: target 
toxicity pT as single-parameter (Œ∏) dose-toxicity curve, K for number of 
doses, R for odds ratio (OR), and Œ± for accuracy. If we use a one-parameter 
logistic model for the dose response curve, we would have a one-parameter 
dose response curve where d is the dose: 
ùúë(ùëë,ùõº)= ùëí3+ùõºùëë
1+ùëí3+ùõºùëë
We will assign a prior probability distribution to the model parameters, 
assigning a prior probability of DLT at each dose based on the available data 
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 10 of 43Protocol STUDY-20-01329
(Legedza, 2001). In order to minimize risk, we will implement a common 
modification to the CRM such that the first patient treated in the study will be 
treated at the lowest available dose (e.g., 100 mg) regardless of the prior 
distribution (Goodman et al, 1995). The study will end when either the 
maximum number of allowable patients treated per protocol is reached (see 
below), or it will end early in the event that the probability that the next 10 
patients to be dosed in the trial will be given the same dose level, regardless 
of DLT outcomes observed exceeds 90% (Zohar and Chevret, 2001).
Rationale for 
Number of SubjectsWith an anticipated screen fail rate of 25%, 54 subjects will be enrolled in 
order to obtain a maximum of 40 eligible subjects.
Phase I studies do not call for hypothesis testing per se. Sample size 
determination for phase I studies therefore are not driven by the usual 
statistical considerations related to type I error rate and estimated power for 
testing specific hypotheses. Planned sample sizes in phase I trials are 
generally dictated by practical constraints, such as the number of sites, 
projected recruitment rates, and number of dose levels. Samples sizes for 
model-based CRM studies typically range between 10 and 50, and the 
optimal sample size can be estimated based on considering model parameters 
that include the TTL (Œ∏) and the number of dosing levels, K. Cheung (2013) 
has provided a sample size calculation package in R. We used his program to 
calculate sample size across a range of ORs along with our study parameters 
of K=7, Œ∏=0.25 and Œ±=0.5. For OR‚Äôs as large as 3.0, N=10 provides an 
accurate estimate of the MTD, while N=48 would be needed for an OR of 
1.5. Therefore our selected maximum sample size of N=40 will likely 
provide an accurate estimate of the MTD while minimizing the number of 
volunteers exposed to potential toxicities of the intervention.
1 BACKGROUND
1) Basic Characteristics 
Harmine is a naturally occurring Œ≤-carboline alkaloid (in Banisteriopsis caapi ). Use of harmine in humans is 
commonly used as part of Ayahuasca which is a hallucinogenic brew made from B. cappi bark and leaves of 
Psychotria viridis [which contain N,N-dimethyltryptamine (DMT)], is consumed recreationally by Amazonian 
tribes and has been studied recently for its potential psychotropic effects. Harmine in ayahuasca inhibits the 
breakdown of DMT and elevates its levels in systemic circulation in the brain. The hallucinogenic effects of 
ayahuasca are attributed to DMT, a 5-HT1A/2A/2C agonist, and harmine in the ayahuasca brew elevates levels 
of DMT in systemic circulation and brain1.
Human studies of harmine have used three different routes: oral, subcutaneous, and intravenous. While most of 
the biological effects of harmine are attributed to its reversible inhibition of monoamine oxidase (MAO) A 
(MAO-A) enzyme, it is also a potent inhibitor of dual specificity tyrosine-phosphorylation-regulated kinase 1A 
(DYRK1A)2. 
2) Relevance to diabetes 
More recently, interest in harmine has emerged as a modulator of insulin release. Harmine has been 
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 11 of 43Protocol STUDY-20-01329
demonstrated to increase human beta cell proliferation to 1-1.5%, a range similar to that which humans 
experience during their first year of life2. Given that human beta cell proliferation strictly decreases 10-14 
months after birth to levels well below this range3 and that this decrease in beta cell proliferation contributes to 
type 1 and type 2 diabetes. Thus, harmine is a potentially revolutionary novel diabetes therapy that targets the 
source of insulin synthesis and is distinct from any currently available treatment. 
3) Brief summary of previous rodent studies of Harmine
3.1 Preclinical Pharmacokinetics
In a pharmacokinetic study of harmine in rats, harmine was orally administered at 20 mg/kg4. The four 
parameters of pharmacokinetics ‚Äì absorption, metabolism, distribution and excretion - were determined. 
Following intravenous injection of harmine, harmine was absorbed by the gastrointestinal tract with an 
absorption time of 3 minutes. Time to achieve maximum concentration of harmine after dosing (Tmax) was on 
average 9.7 minutes. Volume of distribution (Vd) was found to be 3.9 L/kg and harmine‚Äôs bioavailability after 
oral administration was measured to be 3.1%. Lastly, systemic clearance was found to be 103.2 ml/kg/min. 
This rate of clearance is much higher than the rate of hepatic blood blow, suggesting that harmine may 
undergo extrahepatic metabolic processes in addition to hepatic clearance. 
3.2 Preclinical Pharmacodynamics
Numerous studies have investigated harmine‚Äôs therapeutic and behavioral effect in rodents. Together, these 
studies provide insight into harmine‚Äôs safety profile and were used as support for the dosing regimen in this 
study. A specific rodent-to-human conversion factor was used to find the equivalent human dose (see ‚ÄúRationale 
for Dose Determination‚Äù under section 5d for more detail). 
One study investigating the antidepressant effects of harmine administered 10 doses of harmine at 20mg/kg 
over the course of 10 days to mice via injection5. Harmine exerted antidepressant-like effects by protecting 
against increased immobile time in the tail suspension test (TST) and fthe orced swimming test (FST). These 
effects were attenuated with administration of l-Alpha-Aminoadipic Acid (L-AAA), suggesting that harmine 
may induce anti-depressant effects via restoration of astrocytic function5. 
Another study investigating the anti-inflammatory effects of harmine administered 30mg/kg of harmine to 
mice via intraperitoneal injection6. Harmine inhibited NF-Œ∫B transactivity, resulting in reduced mRNA and 
protein levels of NF-Œ∫B downstream inflammatory cytokines. Harmine also prevented inflammatory damage 
of the lung, and decreased serum TNF-Œ±, interleukin-1Œ≤  (IL-1Œ≤) and IL-6 levels in an LPS-challenged mouse 
model. These results indicate that harmine may exert its anti-inflammatory effect by inhibition of the NF-Œ∫B 
signaling pathway6.   
In a study investigating the antioxidant properties of harmine, investigators observed both acute and chronic 
effects of harmine injected at either 5,10 or 15mg/kg in rats7. Acute treatment consisted of only one dose and 
chronic treatment consisted of once a day dosing for 14 days. Both acute and chronic treatment reduced lipid 
and protein oxidation in the prefrontal cortex and hippocampus and also increased superoxide dismutase ad 
catalase activity in the same regions7.
Another study investigating the hypothermic effects of harmine in rats administered 2.5, 5, 10, 15 and 20mg/kg 
of harmine via intraperitoneal injection, showed harmine to produce hypothermic effects over the course of 1 
hour8. Pretreatment with a 5-HT synthesis inhibitor attenuated the hypothermic effect, endogenous 5-HT 
stimulation of 5-HT1A receptor is responsible for hypothermic effects of harmine and other harmala 
alkaloids8.
Lastly, another study explored therapeutic effects of harmine on memory deficits and administered 10, 20 and 
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 12 of 43Protocol STUDY-20-01329
30mg/kg of harmine intragastrically to cognitively dysfunctional mice for 7 days9. Harmine effectively 
ameliorated memory deficits in scopolamine-induced mice with the minimum effective dose being 20mg/kg.
3.2 Preclinical toxicology
In a review of pharmacological and therapeutic effects of harmine, the lethal dose in mice via intravenous 
route was found to be 38mg/kg and the median lethal dose in rats via subcutaneous route was found to be 
200mg/kg. The review also summarized harmine‚Äôs cardiovascular, neurological and antimicrobial effects as 
described below10.
      Cardiovascular Effects
Harmine has vasorelaxant activity which is attributed to its interaction with the alpha 1-adrenergic receptors in 
vascular smooth muscles and also more importantly to its increasing effect on nitric oxide (NO) release from 
the endothelial cells11 . Harmine has been shown to have an ionotropic effect and also decrease heart rate in 
normal anesthetized dogs12. In addition, harmine demonstrated potent angiogenic inhibitory effects, 
significantly decreasing proliferation of vascular endothelial cells and reducing expression of different pro-
angiogenic factors such as vascular endothelial growth factor, NO and pro-inflammatory cytokines13. Finally, 
there is some evidence that harmine may prevent platelet aggregation14 .
Neurological Effects
In traditional medicine, P. harmala, the plant that contains a larger concentration of harmine, has been used 
among societies to treat some nervous system disorders such as Parkinson's disease15 , in psychiatric 
conditions16 such as nervosity17 and to reduce nociception18 . 
As mentioned previously, harmine itself inhibits monoamine oxidase (MAO) enzyme2. Harmine has also been 
shown to increase Brain-derived neurotrophic factor (BDNF) protein19. 
      Osteogenic Activity
Two different studies showed bone anabolic effects of harmine, in vivo and in vitro. It was revealed that 
administration of 10 mg/kg/day of harmine inhibits formation and differentiation of osteoclasts in mice20. 
Adversely, it enhances osteoblast differentiation, most likely via inducing the expression and activation of 
bone morphogenetic protein (BMP) and Runx2 pathways.
4) Previous clinical experience of Harmine 
Radioisotope labeled harmine has been used in human Positron Emission Tomography (PET) studies in order 
to assess central occupancy of MAO-A. In one study, a dose of 370 MBq of intravenous [11C]harmine was 
administered as a bolus for each PET scan. These studies indicated harmine as a suitable molecule for 
quantitative evaluation of MAO-A densities, suggesting it be used to study MAO-A dysregulation in several 
illnesses. 
As mentioned previously, harmine has been administered via oral, subcutaneous, and intravenous route21. In 
one study of physically healthy patients with mental illness, mostly in age group of 18-35 years, 11 patients 
were given oral harmine in dose range 20-960 mg, 6 patients were given subcutaneous harmine between the 
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 13 of 43Protocol STUDY-20-01329
doses of 40-70 mg, and 11 patients were given intravenous harmine in between the doses of 100-300 mg21. 
Authors report that some patients got more than one dose of harmine (specifics are unclear). While authors 
report visual hallucinations with intravenous route, which was administered over 20-30 minutes, they reported 
that harmine was not hallucinogenic by oral or subcutaneous routine. In addition to visual hallucinations that 
occurred only when eyes were closed, authors reported the following adverse reactions with harmine: ‚Äúnausea 
and vomiting, slow, coarse, spontaneous tremor of the extremities of an ‚Äòextrapyramidal‚Äô appearance; 
humming and buzzing noises; ‚Äòwaviness‚Äô of the environment; ‚Äòsinking‚Äô sensations of the body; subjective 
sense of body vibration; and subject numbness that was accompanied by objective evidence of reduced 
sensitivity to light touch and pinprick.‚Äù However, the authors reported, ‚ÄúThese reactions, plus all the 
preceding, occurred in almost every patient with the intravenous route; and (except for hallucinations) some 
occurred with oral dosages higher than the threshold of 300-400 mg. The reactions were generally more 
intense by the former route‚Äù. 
There were no changes in heart rate or blood pressure reported for the group receiving oral administration21. 
However, bradycardia and hypotension occurred with all doses of intravenous harmine, limiting maximum 
dosage to 300 mg intravenously. With the intravenous administration, on average there was a decrease in pulse 
rate of 18 beats/minute and in blood pressure of 16mm mercury. Recovery occurred in about 30 minutes.
Another study administered 40mg of harmine subcutaneously to 40 subjects to explore anti-parkinsonian 
qualities in reserpine, chlorpromazine or encephalitis induced parkinsonism. Harmine showed to be an 
effective anti-parkinsonian agent in patients whose symptoms were induced by Reserpine but not in patients 
whose symptoms were induced by chlorpromazine. There was a wide variety of responses in this therapeutic 
effect of harmine, ranging from slight improvement to complete remission. Harmine also appeared to mildly 
improve the mood of patients. No severe adverse effects were reported in the paper and investigators 
concluded that harmine ‚Äúis safe in man‚Äù22.  
Separately, harmine has been administered and studied as part of the ayahuasca brew23. DMT is the main 
hallucinogenic component of ayahuasca, whereas harmine is a MAO-A inhibitor that attenuates DMT 
breakdown, allowing for a longer lasting effect1. Controlled studies involving oral administration of single 
ayahuasca doses to healthy volunteers show that this botanical hallucinogen induces perceptual alterations, 
introspection, increases in autobiographical memories and positive mood23. These studies also suggest that 
ayahuasca has an acceptable tolerability, with nausea and vomiting as the most frequent adverse reactions. 
4.1 Clinical Pharmacology
One study investigated the pharamacokinetics of Ayahuasca and its alkaloids in healthy volunteers24. Subjects 
ingested a brewed tea containing an average of 252 mg of harmine as well as 35.5 mg DMT, 158 mg THH and 
29.7 mg harmaline. Pharmacokinetic values for harmine were determined for 14 volunteers. Results found 
a C max of 114.8¬±61.7 ng/ml and a T max of 102.0¬±58.3 min. T 1/2 was found to be 115.6 ¬± 60.1 min, k obs was 
measured to be 0.016 ¬±0.027 min-1, C1/F was 271.7¬±180.3 and V ss/F was 49.6 ¬± 40.4 l/kg.
4.2 Clinical Toxicology
The clinical experience of the toxicology of harmine has been discussed above, (see section 2.4). Additionally, 
the toxicity of Ayahuasca, the brew that contains harmine as a significant component has also been 
investigated. In the pharmacokinetic study mentioned above, where subjects received an average of 253mg 
harmine, only 1 out of 15 healthy volunteers vomited24. In a systematic review of uncontrolled ayahuasca use, 
either ritual or recreational, only three case series and two case reports were identified where psychotic 
episodes were associated with ayahuasca intake23. It is important to note that several of the reports describe 
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 14 of 43Protocol STUDY-20-01329
subjects with a personal and possibly a family history of psychosis, nonpsychotic mania, or concomitant use of 
other drugs and also that DMT is believed to be the main hallucinogenic component of ayahuasca and not 
harmine. In conclusion, the controlled use of ayahuasca in experimental and ritual and recreational settings are 
not usually associated with psychotic episodes or intolerable toxicity. 
2 STUDY RATIONALE
The present study is an open label phase 1 dose escalation study in healthy volunteers. The primary goals of 
the trial are to determine the maximum tolerated dose of harmine as well as to characterize the psychoactive 
effects of the drug. A continual reassessment model with 7 doses of harmine at 100 mg, 200 mg, 300 mg, 500 
mg, 700 mg, 900 mg, and 1200 mg will be utilized in order to monitor and determine the tolerability of the 
drug. The results of the study will inform future trials in regard to the safety and efficacy of harmine, which is 
thought to be an alternative medication for diabetes. The present study is a jump-off point for the next phases 
of treatment development. 
Regenerating insulin-producing beta-cells could potentially free millions of diabetes patients from daily doses 
of insulin, and thus, remains an important objective in developing treatments for diabetes. Loss of insulin-
producing beta cells has long been recognized as a cause of type 1 diabetes and has recently been identified as 
an important contributor to type 2 diabetes as well. Though there have been efforts in producing a therapy to 
increase the number of functional beta cells in patients, the major obstacle has been identifying an agent that 
does so by a degree that is actually therapeutic.
Recently, a harmala alkaloid called harmine has demonstrated promise to be an effective therapy for both type 
1 and type 2 diabetes. In-vivo and in-vitro studies have shown harmine to robustly induce beta cell 
proliferation at rates that may have treatment implications. Further specificity studies identified dual specificity 
tyrosine-regulated kinase-1a (DYRK1A) as the likely target for harmine. Harmine occupied the ATP pocket of 
DYRK1A, leading to its inhibition and, ultimately, to beta cell expansion (Wang 2015). Given that harmine‚Äôs 
therapeutic application for diabetes has never been studied in humans, we propose a phase 1 study of harmine 
to pioneer clinical research efforts of this potential new therapy.
Harmine is consumed as part of Ayahuasca which is a hallucinogenic brew made from B. cappi bark and 
leaves of Psychotria viridis [which contain N,N-dimethyltryptamine (DMT)], and used recreationally by 
Amazonian tribes and has been studied recently for its potential psychotropic effects. Harmine in ayahuasca 
inhibits the breakdown of DMT and elevates its levels in systemic circulation in brain reversible inhibition of 
monoamine oxidase (MAO) A (MAO-A) enzyme. The hallucinogenic effects of ayahuasca are attributed to 
DMT, a 5-HT1A/2A/2C agonist.
This study is designed to investigate the safety of oral administration of harmine using an open label, two-
stage, continual reassessment method with 7 doses of harmine at 100 mg, 200 mg, 300 mg, 500 mg, 700 mg, 
900 mg and 1200 mg in healthy volunteers. We anticipate that the proposed study will yield the maximum 
tolerated dose (MTD) for harmine, which will guide future research efforts toward novel diabetes treatments.
2.1 Facilities and Resources 
 
Facilities and Other Resources 
The proposed research will take place at the Icahn School of Medicine at Mount Sinai. 
The research team will benefit from the facilities and resources available at the main 
campus that include specialized laboratories and highly trained personnel. Our research 
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 15 of 43Protocol STUDY-20-01329
team has a strong track of successful inter-Departmental collaborations and several 
ongoing collaborations with the facilities described below. We believe that the teamwork 
demonstrated by the study team and the facilities available at Icahn School of Medicine at 
Mount Sinai will allow for the successfully completion of the current proposal. 
The Mount Sinai Health System 
The Mount Sinai Health System is an integrated health system committed to providing 
distinguished care, conducting transformative research, and advancing biomedical 
education. Structured around seven members hospital campuses and a single medical 
school, the Health System has an extensive ambulatory network and a range of inpatient 
and outpatient services from community-based facilities to tertiary and quaternary care. 
The Health System‚Äôs seven-member hospital campuses include Mount Sinai Beth Israel, 
Mount Sinai Beth Israel Brooklyn, The Mount Sinai Hospital, Mount Sinai Queens, 
Mount Sinai Roosevelt, Mount Sinai St. Luke‚Äôs, and New York Eye and Ear Infirmary of 
Mount Sinai. These hospitals and the entire Mount Sinai network will benefit from 
synergies with the Icahn School of Medicine at Mount Sinai, one of the nation‚Äôs leading 
medical schools, which is on the forefront of medical and scientific training, biomedical 
research, and patient care. The Health System includes approximately 6,600 primary and 
specialty care physicians, 12- minority-owned free-standing ambulatory surgery centers, 
over 45 ambulatory practices throughout the five boroughs of New York City, 
Westchester, and Long Island, as well as 31 affiliated community health centers. 
Icahn School of Medicine at Mount Sinai (ISMMS) 
Icahn School of Medicine at Mount Sinai is among the top twenty medical schools in the 
United States in both NIH funding and in the U.S. News and World Reports survey of 
America's Best Graduate Schools. Driven by a culture of innovation and discovery, 
ISMMS is guided by a $2.25 billion strategic plan that emphasizes translational science. 
The School's 14 multidisciplinary research institutes foster intensive collaboration along a 
continuum that runs from the laboratory to patient care. State-of-the-art laboratories 
support outstanding research, and abundant clinical venues offer superb patient care and 
clinical training opportunities. The 550,000 square foot Leon and Norma Hess Center for 
Science and Medicine, opened in December 2012, allows scientists and physicians to 
work in close proximity and stimulates collaboration that advances efforts to diagnose, 
treat and prevent human disease. Currently, over 1,100 students are enrolled in six degree-
granting programs: MD; PhD in Biomedical Sciences or Neuroscience; Master of 
Biomedical Sciences; Master of Public Health; Master of Science in Genetic Counseling; 
and the Master of Science or PhD in Clinical Research. Approximately 55% of enrollees 
are pursuing a Doctor of Medicine (MD) degree, 25% are working toward a doctoral 
(PhD) degree and 20% are seeking a Master's (MS) degrees. Some students are pursuing 
dual degrees, primarily MD/PhD, MD/MSCR or MD/MPH. ISMMS also offers 
postgraduate research and clinical training opportunities. The School attracts outstanding 
students to its highly competitive programs within an invigorating academic environment. 
The student body is academically excellent and diverse. The Mount Sinai campus is 
located at the border of the Upper East Side, one of the wealthiest neighborhoods in 
America, and East Harlem, a vibrant and largely minority community where 39% of the 
residents live in poverty. East Harlem's rates of infant mortality, childhood asthma, 
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 16 of 43Protocol STUDY-20-01329
obesity, diabetes and hypertension are among the highest in New York City and the 
county. Mount Sinai is a major provider of medical care to both of these communities. 
The Depression and Anxiety Center for Discovery and Treatment (DAC) at ISMMS 
The Depression and Anxiety Center for Discovery and Treatment (DAC) at ISMMS, 
Directed by Project MPI James W. Murrough, M.D., Ph.D., is one of the major research 
and clinical programs of the Department of Psychiatry at ISMMS, with current research 
funding from NIH, non-profit foundations, and industry. Investigators at DAC have a 
long track record in successfully completing studies involving the assessment and 
treatment of individuals with major depressive disorder (MDD), posttraumatic stress 
disorder (PTSD), anxiety disorders and other stress-related disorders. Located on the main 
Manhattan campus of ISMMS, DAC currently includes two full-time psychiatrists, two 
full-time postdoctoral fellows (one in novel therapeutics and one in neuroimaging), two 
PhD-level clinical raters, seven full-time research coordinators, and a data manager. The 
PI and Director of DAC (Murrough JW), has a strong track record of overseeing the 
successful enrollment and completion of clinical research studies conducted in both 
healthy volunteers and in patients with MDD and PTSD. Within clinical research, our 
program has specific expertise in the conduct of prospective clinical trials, including 
phase I through phase IV studies. We have a robust workflow for recruiting and screening 
volunteers for research. In  2019, our clinical research program conducted over 400 
telephone pre-screens and over 150 in-person new evaluations and diagnostic interviews. 
DAC is located on 1399 Park Avenue on the main campus of ISMMS. Available space at 
DAC includes 4 private offices, 2 treatment rooms, one examination/phlebotomy room, 8 
neuropsychology room, a conference room and 9 cubicles for research assistants and 
interns, as well as a comfortable waiting area, the clinic is an ideal setting for screening 
and interviewing potential study participants. The clinic has adequate office space for 
faculty members, research assistants, and post-doctoral fellows. All office space is fully 
equipped with necessary elements for the conduction of the research, including computers 
using a common network, printers, telephone, fax machine, photocopying machines, and 
supplies. 
Psychiatry Infusion Suite 
Harmine administration will take place at the Mount Sinai Psychiatry Infusion Suite, a 
research facility dedicated to supporting early phase and interventional study, located on 
the main campus of the medical school at 1425 Madison Avenue. This facility is equipped 
with continuous vital signs monitoring, infusion pumps and the necessarily medical 
equipment and supplies to support early phase pharmacological studies and 
pharmacokinetic studies. Nurses trained in research protocols provide clinical research 
support to the study physician. A crash cart is available in the infusion suite and a 
responsible study physician is located on site at all times during study procedures. 
Facilities and support for specimen collection and processing is also available. 
The Clinical Research Unit (CRU)
Harmine visits may also occur at The Clinical Research Unit (CRU). The CRU is 
occupying 7500 square feet, is the hub for conducting clinical and translational research at 
Icahn School of Medicine at Mount Sinai. Resources include: private rooms and cubicles, 
telemetry, a core laboratory for specimen processing and short term storage. The staff 
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 17 of 43Protocol STUDY-20-01329
includes nurse practitioners, nurses, a research dietitian, and an information technologies 
specialist. Specimen processing and storage and database support are available. Nursing 
support may be provided for studies undertaken off-unit as well. A research subject 
advocate ensures the safe conduct of studies and to provide assistance with education 
concerning safe and ethical practices.
Mount Sinai Chemistry Clinical Services 
Our Chemistry Laboratory combines modern automation with the personal skills of a 
dedicated team of pathologists, clinical chemists, and technologists. We provide a range 
of services, including routine testing, stat testing, point-of-care testing, and specialized 
tests, and report critical values to providers 24 hours a day, seven days a week. 
Center for Biostatistics at Mount Sinai and Office of Research Services 
The Center for Biostatistics at Mount Sinai at ISMMS (Director: Emilia Bagiella) is an 
academic clinical research center, whose mission is to support the design, conduct, and 
analysis of clinical research studies, including multi-site trials. The Office of Research 
Services (ORS) serves as a central resource for the Mount Sinai Health System (MSHS) 
research community. ORS assists the research community with how to navigate the 
internal research infrastructure and external research agencies; delivers research 
orientation for new faculty and staff; offers consulting services, ongoing training, 
education, and communication support; and provides a wide range of research tools. The 
lead statistician on the proposed project, Dr. Usha Govindarajulu, Ph.D., is senior faculty 
within the Center for Biostatistics and will work closely with PIs Dr. Stewart and 
Murrough to ensure that the proposed projects benefits from the outstanding resources 
and expertise of the Center. Dr. Govindarajulu will work with Dr. Murrough and the 
study database manager to finalize the trial design, the statistical analysis plan, and study 
monitoring and quality assurance plan, as well as the development of the database and the 
data capture instruments. 
Scientific Computing 
Mount Sinai's primary scientific computing resource, named Minerva after the Roman 
goddess of medicine and science, occupies a portion of the 30,000 square feet available in 
our computing facility. Minerva currently has 140 Teraflops peak speed and over 85 
million CPU hours available each year, distributed over more than 300 nodes in the 
cluster with 256 GB of memory per node. These include 9 nodes with general-purpose 
graphics processing units (GPGPU) suitable for image-processing and deep-learning 
projects. Total storage will be expanded to 10 PB in 2018. An archival storage system 
encrypts and saves copies of data on tape to two geographically disparate locations. The 
software and programming environments are the best of breed, and include community 
standards such as Linux and MPI. Over 600 scientific software packages are available and 
regularly updated on Minerva. The workload on the Minerva is controlled by resource 
managers and schedulers that optimize utilization for maximum job throughput or time to 
solution based on the priorities of our scientific community. Minerva achieves well over 
99% uptime, using scalable and reproducible configuration management techniques. 
Rigorous and industry-standard multi-factor authentication and other security policies 
ensure the integrity of the researcher's data and Mount Sinai's compute infrastructure. 
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 18 of 43Protocol STUDY-20-01329
Mount Sinai also employs several domain-specific PhD-level computational scientists 
with interdisciplinary expertise to assist researchers to make efficient and effective use of 
computing resources. These scientists lead basic and advanced training classes and 
accelerate the scientific discovery process by assisting with code development, 
optimization and troubleshooting. They also conduct annual surveys and actively solicit 
and respond to feedback. Additionally, Mount Sinai's robust computing and data cyber 
infrastructure has been designed for the rapid and accurate ingest of the sequencer output, 
and high performance post-processing and analysis by the computational and storage 
infrastructure. The cyber infrastructure resources have been tailored specifically to handle 
the computational and data workflow from the sequencer, including a high bandwidth 
network to the high performance computing and data facilities. Mount Sinai collaborates 
and partners with other facilities and vendors to continuously improve its state-of-the-art 
cyber infrastructure and services. The scientific computing staff track the communities' 
best practices and procedures to ensure that Mount Sinai's computing and data services 
are efficient and effective for its researchers.  
Funding
Funds for this project are supplied through a two year R01 from the National
Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS.
2.2 Risk / Benefit Assessment
Risks to Subjects:
1) Screening evaluation
The risks and discomforts of the screening and baseline evaluations are minimal. No discomfort is expected to 
be associated with the physical examination or the clinical interview. Venipuncture may result in pain and/or 
bruising. In addition, there is a slight possibility of infection.
2) Harmine Administration 
Anticipated side effects include the following; nausea, vomiting, slow, coarse, spontaneous tremor of the 
extremities, humming and buzzing noises, ‚Äòwaviness‚Äô of the environment, ‚Äòsinking‚Äô sensations of the body, 
subjective sense of body vibration, numbness and reduced sensitivity to light touch.
Blood pressure and heart rate are anticipated to decrease by an average of 16mm and 18 beats/minute, 
respectively.  Recovery should be observed after 30 minutes.
The study team will closely monitor possible drug-related DLTs, which are defined as 1). Any serious adverse 
event with causality of at least ‚ÄúPossibly‚Äù or any moderate or severe adverse event with causality of at least 
‚ÄúPossibly‚Äù based on FDA guidelines and MSSM Adverse Event tracking form, or 2). The event that the patient‚Äôs 
systolic or diastolic blood pressure (BP) or heart rate (HR) changes by greater than 20% relative to baseline 
values.
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 19 of 43Protocol STUDY-20-01329
3) Questionnaires
Completing the questionnaires does not pose any risks. It might be a little tedious to repeat the same 
questionnaires over time. Participants may choose to decline to answer certain items and may stop testing at any 
point during the test session.
4) Intravenous catheter insertion
The insertion of the IV catheter may cause momentary discomfort. To minimize this, only experienced DAC 
personnel will perform the procedures involved.
5) Privacy risks
There always exists the potential risk for loss of private information. However, there are procedures in place to 
minimize the risk.
Potential Benefits to Subjects
No direct benefits may result from study participation. All participants will receive without cost an extensive 
psychiatric and medical evaluation. All participants will receive compensation for their participation in the study.
2.3 Recruitment Methods
The vast majority of potential participants for this study will be recruited from the greater NYC metropolitan 
area by media advertisements, including print and internet advertisements. All advertisements will be 
submitted to the IRB for approval prior to posting. Individuals who express interest will be given the 
telephone number of our research program and may call for information about the study. Trained research 
coordinators will briefly describe the study procedures to the potential participants, and if appropriate, will 
schedule the volunteer for the initial screening visit. Informed consent is obtained in person, prior to any 
diagnostic procedures. Interested participants will be screened and those that meet criteria will be offered the 
opportunity to participate in this study.  Subjects will be compensated for the time and inconvenience 
associated with participation in this protocol.
Subjects may also be accepted as referrals from the MAP Screening Protocol (GCO 06-0945: A Screening 
Protocol for Adult Patients with Mood and Anxiety Disorders, Chronic Medical Conditions, and Healthy 
Volunteers; PI: Murrough, MD). The MAP Screening Protocol is not required for participation. The protocol 
is just one of a handful of ways for participants to find our program and therefore find this specific trial. It is 
not a mandatory part of this study and not all subjects will complete it. Part of the screening measures (SCID-
5, self reports) may be completed under the MAP Screening Protocol as long as the assessments are 
completed within 6 weeks of the participant signing consent for the present protocol.
The MAP screening protocol is a protocol our program uses to screen every potential research participant. In 
other words, this protocol is the entry point into our program and is used to assess eligibility for any other 
research protocols that our program is running. A participant screened under this protocol may go on to 
participate in several other research protocols, or may only participate in the screening protocol if he/she is 
deemed ineligible for any other protocols. Because some of the assessments in the MAP screening protocol 
overlap with the assessments done in this proposed protocol (I.e. a diagnostic assessment, clinical self-report 
measures), we would not ask a participant to repeat these if he/she had completed the screening in the MAP 
Screening Protocol within the past 6 weeks and was interested in participating in the present study. For 
instance, a patient who had undergone a SCID-V assessment under the MAP Screening Protocol would not 
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 20 of 43Protocol STUDY-20-01329
be asked to undergo the MINI-7 as a part of screening for the present study as these assessments serve the 
same purpose as diagnostic tools. 
The screening protocol specifically states that "data derived from [their] participation may be used‚Ä¶ in a 
number of ways including: to make theories for future research, for any future DAC research protocols in 
which you participate‚Ä¶" It also asks participants to initial if they give DAC permission for future contact 
regarding additional study participation. A participant would only be re-contacted to participate in this 
proposed study if and only if they had given consent for future contact.
3 STUDY OBJECTIVES
3.1 Primary Objective
Aim 1: The principal goal of our clinical trial is to establish the Maximum Tolerated Dose (MTD) of 
harmine in healthy patients that will inform the recommended phase II dose.
Hypothesis 1.1: Orally administered harmine will be well-tolerated with minimal dose-limiting toxicities at 
our testing doses.
3.2 Secondary Objectives
Aim 2: Characterize psychoactive effects of harmine in healthy adults.
Hypothesis 2.1: Orally administered harmine will be well-tolerated and will not induce burdensome 
psychoactive effects in healthy adults.
4 STUDY DESIGN
4.1 Study Overview
Definition of Maximum Tolerated Dose (MTD)
In this modified Continual Reassessment Model (CRM) approach, the MTD is defined as the dose with a toxicity 
level closest to the target toxicity level of 25%. The CRM final MTD estimate is that dose that would have been 
given to the (N+1)st patient in the trial.
Definition of Dose Limiting Toxicity (DLT) 
a) A serious adverse event with causality of at least ‚ÄúPossibly‚Äù related to the study drug or 
b) A non-serious adverse event rated as at least moderate and ‚ÄúPossibly‚Äù related to the study drug
c) The event that the subject experiences any of the following psychiatric symptoms
i) Visual hallucinations 
ii) Humming or buzzing noises
iii) Sensations of sinking, body vibrations or waviness of the environment
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 21 of 43Protocol STUDY-20-01329
d) The event that the subject develops any of the following changes in vital signs within 6 hours following 
administration of study drug:
i) Symptomatic hypotension, or > 20% decrease in systolic blood pressure (SBP) from pre-dosing and 
an absolute SBP < 90; or 
ii) Symptomatic hypertension, or > 20% increase in SBP or diastolic blood pressure (DBP) from pre-
dosing and absolute SBP > 170 or DBP > 95;
iii) New onset tachycardia (heart rate >100 bpm) and >20% increase from pre-dosing; or symptomatic 
bradycardia (heart rate <60 bpm) and > 20% decrease from pre-dosing.
Relationship Attribution Description 
Unrelated to 
investigational drugUnrelated AE is clearly NOT related 
to intervention 
Unlikely AE is doubtfully related to 
intervention
Possible AE may be related to 
intervention
Related to investigational 
drugProbable AE is likely related to 
intervention
Definite AE is clearly related to 
intervention
Table 1. Causal relationship between adverse event and investigational drug
Dose Escalation Rules
Generally, the CRM starts by selecting a target dose-limiting toxicity rate and a mathematical model 
assumed to govern the relationship between dose and toxicity; the prior dose-toxicity curve. After outcomes 
are observed (i.e., a patient experiences a DLT or not), the dose-toxicity curve is refit incorporating the 
latest outcome. The next dose assigned is that which is most likely to be associated with the target toxicity 
level (the MTD). At every step, the next patient is assigned the dose estimated to be nearest to the MTD.
While the ‚Äú3 + 3‚Äù design is the most commonly employed dose finding design, the CRM is generally 
accepted by statisticians as superior due to two main advantages: (1) the CRM provides a mechanism for 
stopping at a specified toxicity level, whereas the targeted toxicity rate for the MTD from the ‚Äú3 + 3‚Äù 
design is necessarily in the range of 16%-33%, and (2) the CRM is more efficient; it can establish the 
MTD more accurately and precisely from fewer patients and it minimizes the number of patients treated at 
unsafe doses. Initial criticisms of the CRM, largely that unsafe escalation could occur too quickly, have 
been addressed by modifications to the original approach.  Our implementation of the CRM will include 
modifications that prohibit steep dose escalations and will include the standard safety considerations of the 
traditional designs.
We will implement a series of precedented safety modifications to the original CRM design suggested by 
O‚ÄôQuigley et al. in order to ensure subject safety. The first modification will be to start dosing from the 
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 22 of 43Protocol STUDY-20-01329
lowest dose, far below the expected MTD, instead of starting at the prior MTD estimate (Wheeler 2019). 
Secondly, we will not skip untested dose levels when escalating doses in order to reduce the number of 
subjects exposed to potentially toxic doses. However, we can skip doses when de-escalating if the CRM 
recommends doing so (Wheeler 2019). Lastly, we will enforce coherent dose-escalation, where if the last 
patient has a DLT, the next patient will not receive a dose higher than that of the last patient, even if the 
model recommends it (Faries D 1994). These modifications are simple to implement and help to prevent 
overdosing subjects.
Dosing Design
We will employ the CRM with the following design parameters:
a. The target dose limiting toxicity rate is 25%.
b. 7 pre-defined dose levels: 100mg, 200mg, 300mg, 500mg, 700mg, 900mg and 1200mg with 
assumed prior toxicity rates of 2%, 5%, 10%, 20%, 30%, 50% and 65%.
c. Model for dose-toxicity:
1. A maximum of 40 evaluable patients. We do not plan to implement any stopping criteria 
(other than for toxicity). In the absence of DLTs we plan to enroll all 40 patients in order 
to increase the precision of the estimated MTD.
Rationale for Dose Determination
The dose escalation for this Phase 1 study in healthy subjects described herein is based on the experience 
during the dose escalation study of harmine in medically healthy subjects with varying mental disorders21 
and supported by the preclinical rodent data described in section 2 above. Dose determination was guided 
by results of both orally and intravenously administered harmine. 11 subjects received oral harmine at 
doses between 20-960 mg and 11 subjects received IV harmine between 100-300 mg. All subjects were 
observed for 72 hours. It is important to note that 5 subjects out of the total 29 had auditory hallucinations 
or delusions before study enrollment and that the results section does not differentiate between the 
outcomes of these subjects and others. Hence, adverse event results may be confounded by subject 
susceptibility to experience psychiatric symptoms.
Oral Administration Results and Contribution to Dose Determination
Authors report that harmine was not hallucinogenic and did not change heart rate or blood pressure at any 
dose when given via oral route21. Harmine did, however, induce some (unclear on which) of the following 
mild to moderate adverse events when given above 300mg orally; nausea and vomiting, tremors, humming 
and buzzing noises, ‚Äòwaviness‚Äô of the environment; ‚Äòsinking‚Äô sensations of the body, subjective sense of 
body vibration, numbness and reduced sensitivity to touch. Given that no serious or severe adverse events 
were reported for oral dosing up to the maximum administered dose of 960mg, we concluded that 
escalating from 100mg to at least 900mg using the modified Fibonacci sequence is warranted.
Intravenous Administration Results and Contribution to Dose Determination
In order to interpret results of the IV administration of harmine for the purpose of our oral administration 
study, we converted the IV dose to its equivalent oral dose. By definition, bioavailability of a drug given 
by IV is 100% because the drug is administered directly into the vascular space. Pharmacology studies 
indicate that harmine has relatively poor bioavailability via oral route, with results varying between 3-
5.33% 25. In an effort to remain conservative, we assumed double the upper limit of bioavailability and 
multiplied the IV dose by 10 in order to get the equivalent oral dose.
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 23 of 43Protocol STUDY-20-01329
The threshold hallucinogenic dose through IV from the previously mentioned clinical study was between 
150-200mg (equivalent to 1500-2000mg orally), with 5 out of 11 subjects reporting close-eye 
hallucination21. Bradycardia and hypotension limited the maximum IV dose to 300mg (oral equivalent = 
3,000mg), almost double our highest proposed dose. Aside from closed-eye hallucinations, subjects 
receiving harmine via IV also experienced the mild to moderate adverse events mentioned above. 
Although bradycardia and hypotension can be serious adverse events, the limiting dose due to these 
parameters in this study is double what we are proposing to escalate to. Coupled with our conservative 
estimate of bioavailability, these results make our maximum potential dose of 1200mg a reasonable upper 
limit in our effort to identify harmine‚Äôs maximum tolerated dose. 
Preclinical Rodent Data and Contribution to Dose Determination 
As described in the background section, numerous studies have been conducted administering harmine to 
rodents, some of which have included multiple administrations over the course of one to two weeks. We 
used rodent studies with extended administrations of harmine and lengthy observational periods to help 
inform dose determination. 
In order to convert the animal dose to a human equivalent dose (HED), we utilized allometric scaling. 
Allometric scaling is an empirical approach where the exchange of drug dose is based on normalization of 
dose to body surface area. This approach assumes that there are some unique characteristics on 
anatomical, physiological, and biochemical process among species, and the possible difference in 
pharmacokinetics/physiological time is accounted by allometric scaling 26. This method is frequently used 
to predict an approximate dose on the basis of data existing in other species. 
In order to convert a mouse or rat dose in mg/kg to human equivalent dose, we divide the animal dose by 
12.3 or 6.2, respectively27. Following this conversion, we found the HED for two of the described studies 
while taking into account route of administration and bioavailability. The HED from the study that 
administered 20mg/kg harmine to mice via injection for 10 days is 1.62mg/kg 5. For an average American 
male, this correlates to 144mg of harmine as if it was administered via IV. Converting this to an oral dose 
equivalent using our conservative 10% estimate translates this to a 1440mg oral dose. The HED from the 
study where rats were given 15mg/kg harmine via injection once a day for 14 days is 2.4mg/kg 7. The 
equivalent IV and oral dose in the average male are 215mg and 2,150mg, respectively. 
The fact that the animal subjects were healthy enough to undergo behavioral testing and observation for 
10 to 14 days suggests that the doses of harmine administered were not toxic. Converting these doses to 
their HED of 1440mg and 2150mg provides support for the dosing regimen outlined above.
Choice of model
Our study will employ the continual reassessment method (CRM) to find a MTD of harmine (O'quigley 1990). 
The model-based CRM approach has been shown to be more accurate in targeting the MTD and more efficient 
in terms of requiring fewer volunteers, compared to more traditional ‚Äú3+3‚Äù rule-based approaches for phase I 
studies. The CRM uses a statistical model to estimate the relationship between dose and DLT risk, which then 
informs dose escalation decisions. Generally, the CRM starts by selecting a target DLT rate and a 
mathematical model assumed to govern the relationship between dose and toxicity: the prior dose-toxicity 
curve. After outcomes are observed (i.e., a patient experiences a DLT or not), the dose-toxicity curve is re-fit 
incorporating the latest outcome. The next dose assigned is that most likely to be associated with the target 
toxicity level (the MTD). At every step, the next patient is assigned the dose estimated to be nearest to the 
MTD. Our implementation of the CRM utilizes a one-parameter exponential (or empiric) model, the model 
originally proposed by O'Quigley et al. We will employ the model with a logistic one-parameter prior for the 
model parameter Œ±. We have chosen this model for two principal reasons; its simplicity and efficiency. 
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 24 of 43Protocol STUDY-20-01329
Generally, the one-parameter model is more efficient than two parameter models. That is, it requires fewer 
patients to precisely estimate that aspect of the dose-toxicity curve that is allowed to vary (the slope or 
steepness parameter). This increased efficiency in parameter estimation may come at the cost of a slight 
decrease in the accuracy of depicting the entire dose-toxicity relationship. However, the CRM has proven to be 
robust in choosing an MTD, even if the functional form is moderately incorrect. In large part this robustness is 
due to the fact that the CRM is not concerned with accurately estimating all aspects of the dose-toxicity curve, 
but rather the area near the location of the MTD.
5 CRITERIA FOR EVALUATION
5.1 Primary Endpoint
The primary endpoint of our clinical trial is to establish the Maximum Tolerated Dose (MTD) of 
harmine in healthy patients in a phase I dose escalation study for efficacy testing in phase II trials. See 
above for MTD and DLT definitions where safety is the primary endpoint.
5.2 Secondary Endpoints
A secondary endpoint is to characterize psychiatric effects of orally administered harmine in healthy adults. 
5.3 Safety Evaluations
We will be continuously assessing for AE/SAEs through the CRM model and through the questionnaires, we 
will administer as outlined in Table 2.
5.4 Other Evaluations
N/A
6 SUBJECT SELECTION
6.1 Study Population
Healthy adults ages 18-55. 
6.2 Inclusion Criteria
Inclusion Criteria 
‚Ä¢ Male or female aged 18-55 years;
‚Ä¢Rationale: We wish to exclude children under the age of 18 and adults over the age of 55 in 
part due to concerns regarding neurodevelopmental and neurocognitive effects, respectively. 
‚Ä¢ Participants must have a level of understanding of the English language sufficient to agree to all tests 
and examinations required by the study and must be able to participate fully in the informed consent 
process;
‚Ä¢ Body Mass Index (BMI) between 19 and 30;
‚Ä¢Rationale: We wish to exclude individuals who are underweight as defined as a BMI <19, or 
who are obese as defined as >30 according to the Centers for Disease Control (CDC). These 
criteria are in line with the goals of a phase I dose finding and pharmacokinetic study. 
‚Ä¢ Women of childbearing potential and men must be using an acceptable method of contraception to 
avoid pregnancy throughout the study as judged by the investigator;
‚Ä¢ Women must not be breastfeeding;
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 25 of 43Protocol STUDY-20-01329
6.3 Exclusion Criteria
Exclusion Criteria
‚Ä¢ Presence of a significant medical illness i.e., delirium, metastatic cancer, decompensated cardiac, liver 
or kidney failure, major surgery, stroke or myocardial infarction during the three months prior to entry;
‚Ä¢ Presence of a significant neurological disease such as Parkinson's disease, primary or secondary 
seizure disorders, intracranial tumors, severe head trauma; neurodegenerative diseases;
‚Ä¢ Presence of neurocognitive or dementing disorders;
‚Ä¢ Presence or history of psychiatric disorder as diagnosed by Mini Neuropsychiatric Interview (MINI);
‚Ä¢ Urine toxicology positive for illicit drugs or dis-allowed concomitant medications as per study 
protocol;
‚Ä¢ Medications with primary central nervous system (CNS) effects are dis-allowed, including 
psychotropic medications, antidepressants, benzodiazepines, centrally acting hypnotic agents, and 
centrally acting anti-migraine therapies;
‚Ä¢ Medications with primary cardiovascular effects are dis-allowed, including beta-adrenergic 
antagonists, ACE inhibitors, calcium channel blockers, and diuretics;
‚Ä¢ Any OTC medications or herbal remedies (see concomitant medications listed above) that could 
interfere with the study drug, pose a risk to the subject, or contain high tyramine as outlined in the 
Low Tyramine Diet attachment and above in the concomitant medication summary;
‚Ä¢ Any other medications that, in the opinion of the investigators, would pose a safety risk to the patient 
or that would interfere with the interpretation of study results;
‚Ä¢ Positive pregnancy test at screen or on the morning of the treatment day in women of childbearing 
potential;
‚Ä¢ Systolic blood pressure outside the range of 100 - 140 mmHg, diastolic blood pressure outside the 
range of 60 - 90 mmHg, and pulse rate at rest > 100 or < 60 bpm;
‚Ä¢ History of positive tests for hepatitis B surface antigen, hepatitis C antibodies;
‚Ä¢ History of HIV;
‚Ä¢ Significant ECG abnormalities as follows:
‚Ä¢ Heart Rate < 60 and >100 bpm
‚Ä¢ PR Interval <120 and > 220 ms
‚Ä¢ QRS duration < 70 and >120 ms
‚Ä¢ QTC Interval (Bazett) > 450 ms
    Clinically significant abnormalities at screening or morning of visit
‚Ä¢ Systolic blood pressure outside the range of 100 - 140 mmHg, diastolic blood pressure outside the range 
of 60 - 90 mmHg, and pulse rate at rest > 100 and < 60 bpm.
‚Ä¢ History of positive tests for hepatitis B surface antigen, hepatitis C antibodies, and HIV.
‚Ä¢ Positive urine drug test at screening and morning of dosing.
‚Ä¢ Significant ECG abnormalities as follows:
‚Ä¢ Heart Rate < 60 and >100 bpm
‚Ä¢ PR Interval <120 and > 220 ms
‚Ä¢ QRS duration < 70 and >120 ms
‚Ä¢ QTC Interval (Bazett) > 450 ms
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 26 of 43Protocol STUDY-20-01329
7 CONCURRENT MEDICATIONS
Concurrent medications are prohibited for this study. See the I/E criteria above for detail. 
7.1 Allowed Medications and Treatments
See the I/E criteria above for details about concomitant medications.
7.2 Prohibited Medications and Treatments
See the I/E criteria above for details about prohibited medications.
8 STUDY PROCEDURES AND GUIDELINES
8.1 Clinical Assessments
A Schedule of Events representing the required testing procedures to be performed is diagrammed in 
Appendix 1 and described in more detail in Table 2.
Prior to conducting any study-related activities, written informed consent and the Health Insurance Portability 
and Accountability Act (HIPAA) authorization must be signed and dated by the subject or the subject‚Äôs 
legally authorized representative.
8.1.1 Diagnostic Assessment
A psychiatric diagnostic assessment will be performed to assess current and past psychiatric disorders. This 
may be assessed using the SCID-5, MINI, or any other standard clinical diagnostic instrument.
8.1.2 Self-Report Questionnaires
Self-report scales, assessing symptoms of depression and anxiety and related sequelae and experiences, will 
be administered either by paper-and-pencil form or via secure online survey tool (REDCap).
8.1.3 Concomitant Medications
All concomitant medication and concurrent therapies will be documented at screening. Dose, route, unit 
frequency of administration, and indication for administration and dates of medication will be recorded as 
available. Concomitant medications are largely prohibited as outlined in the I/E criteria above. 
8.1.4 Demographics
Demographic information (date of birth, gender, race) will be recorded at screening.
8.1.5 Medical History
Relevant medical history, including history of current disease, other pertinent history, and information regarding 
underlying diseases will be recorded at screening.
8.1.6 Adverse Events
Information regarding occurrence of adverse events will be captured throughout the study. Duration 
(start and stop dates and times), severity/grade, outcome, treatment and relation to study participation 
will be recorded on the case report form (CRF).
8.1.7 Urine Toxicology Test (UTOX)
A rapid urine toxicology test (UTOX) may be performed at the DAC offices. Results will not be  posted in the 
participant‚Äôs medical record. 
8.1.8 Pregnancy Test
A urine or serum pregnancy test may be obtained from female subjects who are of  childbearing potential.
8.1.9 Urinalysis
Urine may be obtained and sent to the site‚Äôs clinical laboratory for determination of a routine 
urinalysis and drug of abuse screen.
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 27 of 43Protocol STUDY-20-01329
9 EVALUATIONS BY VISIT
Psychiatric interview tools to be used
1. The Mini Neuropsychiatric Interview (MINI-7) is a diagnostic interview used to determine psychiatric 
diagnoses in research settings based on DSM-V criteria. The brief structured interview assesses the 17 
psychiatric disorders that are thought to be most prevalent (Sheehan et al., 1998).
2. The Visual Analogue Scales (VAS) (Bond and Lader 1974) are used to assess subjective state 
changes. They are 100-mm horizontal lines marked proportionately to the perceived intensity of the 
subjective experience (0=not at all, to 10=extremely) for the following states: anxious, depressed, 
drowsy, high, hungry, nauseous, control/dominance, happiness/pleasure, excitement/arousal, and 
vividness of image.
3. The Perceived Stress Scale (PSS) (Cohen et al. 1983) is a 10-item scale that measures the perception 
of stress. Each item is rated on a 5-point scale ranging from never (0) to almost always (4). Positively 
worded items are reverse scored, and the ratings are summed, with higher scores indicating more 
perceived stress. PSS-10 scores are obtained by reversing the scores on the four positive items: For 
example, 0=4, 1=3, 2=2, etc. and then summing across all 10 items. Items 4, 5, 7, and 8 are the 
positively stated items. 
4. The Columbia Suicide Severity Rating Scale (C-SSRS) (Posner et al. 2011) is a suicidal ideation and 
behavior rating scale used to evaluate suicide risk. The C‚ÄêSSRS is made up of ten categories, all of 
which maintain binary responses (yes/no) to indicate a presence or absence of the behavior. The ten 
categories included in the C‚ÄêSSRS are as follows: Category 1 ‚Äì Wish to be Dead; Category 2 ‚Äì 
Non‚Äêspecific Active Suicidal Thoughts; Category 3 ‚Äì Active Suicidal Ideation with Any Methods 
(Not Plan) without Intent to Act; Category 4 ‚Äì Active Suicidal Ideation with Some Intent to Act, 
without Specific Plan; Category 5 ‚Äì Active Suicidal Ideation with Specific Plan and Intent; Category 
6 ‚Äì Preparatory Acts or Behavior; Category 7 ‚Äì Aborted Attempt; Category 8 ‚Äì Interrupted Attempt; 
Category 9 ‚Äì Actual Attempt (non‚Äêfatal); Category 10 ‚Äì Completed Suicide.   A yes/no binary 
response is also utilized in assessing self‚Äêinjurious behavior without suicidal intent. The outcome of 
the C‚ÄêSSRS is a numerical score obtained from the aforementioned categories. 
5. The Brief Psychiatric Rating Scale (BPRS) (Overall and Gorham, 1962) is a clinician-administered 
assessment used to capture acute behavioral changes throughout treatment. The scale includes 16 
items each aimed at assessing components of psychosis including 4 items assessing positive (+) 
symptoms of psychosis such as conceptual disorganization, hallucinatory behavior, suspiciousness, 
and unusual thought content. Another 3 items assess negative (-) symptoms of psychosis such as: 
blunted affect, emotional withdrawal, and motor retardation. The remaining items assess activation 
and hostility by capturing tension, mannerisms and posturing, uncooperativeness, and grandiosity. 
Items that assess guilt, anxiety, depressed mood, and somatic concerns are also present. 
6. The Patient Rated Inventory of Side Effects (PRISE) is an adverse Event Visit Checklist is a clinician-
administered questionnaire used to qualify side effects by identifying and evaluating the tolerability of 
each symptom.
7. The bipolar version of the Profile of Mood States (POMS-Bi) is a 72-item psychological rating scale 
used to assess transient, distinct mood states. Items are rated on a 4-point scale from 0, ‚Äúmuch unlike 
this‚Äù to 3, ‚Äúmuch like this‚Äù. It includes six bipolar scales; composed-anxious, agreeable-hostile, 
elated-depresses, confident-unsure, energetic-tired, and clearheaded-confused. It is also a useful 
instrument in identifying the effects of drug treatments (O‚ÄôHalloran et al., 2004).
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 28 of 43Protocol STUDY-20-01329
While paper-and-pencil versions of self-report scales will be available, should participants express a preference 
for them, standard protocol will be to administer these measures via REDCap, a secure, password-protected 
web application for the development and management of surveys and databases. While participants will be able 
to access their own databases (with research team help), they will not be able to access anyone else‚Äôs data. All 
participants will enter a subject code rather than an individually identifying PHI for purposes of self-report 
measures. Participants will be given opportunity to fill out these measures via computers in our offices. REDCap 
has a save-and-continue feature, which provides a session- and subject-specific code for continuation should 
participants desire to complete assessments off-site, further reducing participant burden.
9.1 Screening Visit (V0)
After receiving complete disclosure about the research and being given the opportunity to fully review the 
consent form, potential participants will be encouraged to ask the investigators questions. If they choose to 
take part in the study, they will be asked to provide written informed consent. 
All participants will also undergo a diagnostic assessment, using the SCID‚ÄìV or the MINI, in order to 
determine diagnosis. Screening measures may be completed under the screening protocol "A Screening 
Protocol for Adult Patients with Mood and Anxiety Disorders, Chronic Medical Conditions, and Healthy 
Volunteers" (GCO: 06-0945; PI Dr Murrough), as long as the assessments are completed within 6 weeks of the 
participant signing consent for the present protocol.
At the screen all participants will receive:
1) Psychiatric Assessments
a) MINI for psychiatric history (if a diagnostic assessment has not been completed already 
within the past 6 months under a DAC protocol.
b) C-SSRS
c) BPRS 
d) Concomitant medication log
2) Medical Assessments
a) Medical history (Hx)
b) Physical examination (PE)
c) Vital signs (VS)
d) Electrocardiography (ECG)
e) Laboratory Tests: CBC, CMP, UTox, U/A, TSH 
f) Urine tests: Drug abuse screen, Urinalysis, Pregnancy test (if applicable)
The study investigators will review the psychiatric interviews and medical assessments and identify eligible 
participants. The screening visit may occur on 2-3 separate days. All screening procedures will be completed 
before the Treatment visit - visit V1, and within four weeks of the treatment visit. As long as the screening 
assessments are completed within four weeks of the signing of consent for this protocol, the screening 
measures will not be repeated. Those found eligible based on screening assessment will be scheduled for the 
treatment visit within 4 weeks upon completion review of all screening procedures. Upon scheduling a 
baseline visit, eligible participants will be instructed to begin the low tyramine diet discussed during screening 
3 days before the scheduled treatment visit. Participants will be routinely reminded by a member of the study 
team 4 days before a given treatment visit to begin the low tyramine diet the following day and see if the 
participant has any questions. Participants will also be systematically reminded 24 hours before their treatment 
visit to avoid food and drink at least 8 hours before dosing is set to begin. Adherence to the low tyramine diet 
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 29 of 43Protocol STUDY-20-01329
and the 8-hour NPO will be confirmed and recorded by the study clinician at the beginning of the treatment 
visit.
9.2 Treatment Visit (V1)
Refer to Table 2 for Visit 1 procedures.
9.3 Follow-up/Study Exit (V2)
Post-Baseline: approximately 24 hours after the oral dose
a) Brief physical and interval medical history
b) Update AE and con-med log
c) Collect blood sample
      a. 10 mL plasma
      b. 3-5mL serum 
d) Clinical Scales/Self-Reports
a. C-SSRS
b. BPRS
c. POMS
d. PRISE
e. PSS
f. VAS
        Study exit: Physician assessment followed by decision for discharge using standardized assessment scale  
Table 2. Treatment Visit (Visit 1) Procedures 
Time Procedures
-90 min‚Ä¢ Subject arrives at Infusion Suite or CRU
‚Ä¢ Name and number for escort home is collected 
‚Ä¢ Vitals*
‚Ä¢ Urine tests: Drug abuse screen, Urinalysis, Pregnancy test (if 
applicable)
‚Ä¢ Study doctor confirms 8-hour NPO 
‚Ä¢ Study doctor confirms adherence to low tyramine diet for 
past 72 hours
‚Ä¢ Clinical assessments
‚Ä¢ C-SSRS
‚Ä¢ BPRS
‚Ä¢ POMS
‚Ä¢ PRISE
‚Ä¢ PSS
‚Ä¢ VAS
‚Ä¢ Insertion of Hep-lock
‚Ä¢ Baseline plasma and Serum sample: 1 ETDA and 1 SST
-10 min ‚û¢Pre-treatment baseline of vital signs: vital signs will 
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 30 of 43Protocol STUDY-20-01329
be taken following 5 minutes of rest, with the average 
of two taken 5 minutes apart.
0 min ‚û¢Oral Administration of Harmine
+30 min ‚û¢Vital signs
‚û¢PRISE
‚û¢VAS
‚û¢Plasma and Serum sample: 1 ETDA and 1 SST
+60 min ‚û¢Vital signs
‚û¢PRISE
‚û¢VAS
‚û¢Plasma and Serum sample: 1 ETDA and 1 SST
+90 min ‚û¢Vital signs
‚û¢PRISE
‚û¢VAS
‚û¢Plasma and Serum sample: 1 ETDA and 1 SST
+ 120 min ‚û¢Vital signs
‚û¢PRISE
‚û¢BPRS
‚û¢VAS
‚û¢POMS
‚û¢Plasma sample
+180 min ‚û¢Vital signs
‚û¢PRISE
‚û¢VAS
‚û¢Plasma and Serum sample: 1 ETDA and 1 SST
+ 240 min ‚û¢Vital signs
‚û¢PRISE
‚û¢VAS
‚û¢Plasma sample
+ 300 min ‚û¢Vital signs
‚û¢PRISE
‚û¢VAS
‚û¢Plasma sample
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 31 of 43Protocol STUDY-20-01329
+360 min ‚û¢Vital signs
‚û¢C-SSRS
‚û¢BPRS
‚û¢POMS
‚û¢PRISE
‚û¢VAS
‚û¢PSS
‚û¢Plasma and Serum sample: 1 EDTA and 1 SST
+420 min ‚û¢Vital signs
‚û¢C-SSRS
‚û¢BPRS
‚û¢POMS
‚û¢PRISE
‚û¢VAS
‚û¢PSS
‚û¢Plasma sample
+480 min ‚û¢Vital signs
‚û¢C-SSRS
‚û¢BPRS
‚û¢POMS
‚û¢PRISE
‚û¢VAS
‚û¢PSS
‚û¢Plasma sample
Readily for 
discharge 
home ‚û¢P
hysician assessment followed by decision for 
discharge 
‚û¢P
articipants picked up by pre-designated escort home
*Prior to each vital sign, measurement the subject will be resting quietly for a minimum of five minutes before 
the vital signs are measured. For each specified vital sign time point, two readings will be taken 5 minutes 
apart and the average of the two readings will be used.
a) Safety parameters for monitoring
‚Ä¢ Psychosis / mental status changes: BPRS, other clinical scales
‚Ä¢ PRISE: nausea, vomiting, diarrhea and other general adverse events
‚Ä¢ Vitals: BP, HR, Temp, Respiration
‚Ä¢ Unanticipated effects: spontaneous reporting and structured assessment with the PRISE
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 32 of 43Protocol STUDY-20-01329
b). Plasma and Serum sampling
At screening, blood will be drawn for clinical screening labs including chemistry and hematology. For this 
purpose up to 16mL of blood will be drawn. On a separate treatment day, blood will be collected at eight 
timepoints over approximately eight hours for pharmacokinetic analysis. At each of these timepoints, 4mL 
of blood will be drawn. A 10ml of blood will be collected at timepoints -90, +60, +90, +180, +360 minutes 
and +24 hours for immune cell characterization in addition to pk analysis. At the same timepoints 3-5mL 
of serum will be drawn for analysis of c-peptides, insulin, and glucose. 
c). Dosage of Harmine
The doses of harmine for oral administration are 100mg, 200mg, 300mg, 500mg, 700mg, 900mg and 
1200mg. The rationale for using these doses is based on the modified Fibonacci sequence (i.e. 1, 2, 3.3, 5, 
7, 9, 12, 16‚Ä¶) that is widely used in Phase I clinical trials (Le Tourneau, Lee et al. 2009).
d) Drug source, storage and preparation
a) Source: Harmine will be provided and compounded by The University of Minnesota College of 
Pharmacy ITDD.
b) Harmine will be stored by the Investigational Drug Service (IDS) of the Mount Sinai Pharmacy
c) The manufacturing process of harmine consists of purification from the plant followed by salt 
formation to form harmine HCL under GMP conditions.
10 ADVERSE EXPERIENCE REPORTING AND DOCUMENTATION
10.1 Adverse Events
An AE is any untoward medical occurrence in a study subject administered an investigational 
product and that does not necessarily have a causal relationship with a treatment.
An AE therefore can be any unfavorable and unintended sign (including laboratory finding), 
symptom or disease temporally associated with participation in an investigational study, whether 
or not considered drug-related. In addition to new events, any increase in the severity or 
frequency of a pre-existing condition that occurs after the subject signs a consent form for 
participation is considered an AE. This includes any side effect, injury, toxicity, or sensitivity 
reaction.
Any condition, laboratory abnormality, or physical finding with an onset date prior to the subject 
signing consent for study participation is considered to be pre-existing in nature and part of the 
subject‚Äôs medical history.
AE Severity
Table 1. AE Severity Grading
Severity (Toxicity Grade) Description
Mild (1) Transient or mild discomfort; no limitation in activity; no medical 
intervention or therapy required. The subject may be aware of the 
sign or symptom but tolerates it reasonably well.
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 33 of 43Protocol STUDY-20-01329
Moderate (2) Mild to moderate limitation in activity, no or minimal medical 
intervention/therapy required.
Severe (3) Marked limitation in activity, medical intervention/therapy required, 
hospitalizations possible.
Life-threatening (4) The subject is at risk of death due to the adverse experience as it 
occurred. This does not refer to an experience that hypothetically 
might have caused death if it were more severe.
AE Relationship to Study Drug
1). Attribution of Adverse Events:
      No: Adverse events are clearly not related to the investigational agents
      Unlikely:  Adverse events are doubtfully related to investigational agents
      Possibly:  Adverse events may be related to investigational agents
      Probably: Adverse events are likely related investigational agents
      Definitely:  Adverse events are clearly related to the investigational agents
2). Plan for grading adverse events:
      The FDA‚Äôs definition of serious adverse events (21 CRF 312) include any untoward medical occurrence 
that at any time results in death or the immediate risk of death, hospitalization or the prolonging of an 
existing hospitalization, persistent or significant disability/incapacity or congenital anomaly/birth defect 
(NOH Guide, 6/11/99).
     Grades of Risk:
     1 = Non-Serious Adverse Event
     2 = Serious Adverse Event
The PI will report all serious adverse events, verbally and in writing, to the Mount Sinai IRB within 48 hours.
10.2 Serious Adverse Experiences (SAE)
An SAE is defined as any AE occurring at any dose that results in any of the following 
outcomes:
ÔÇ∑Death
ÔÇ∑Life threatening experience defined as any adverse experience that places the subject, in the 
view of the treating physician, at immediate risk of death at the time of occurrence; ie, it does 
not include a reaction that, had it occurred in a more severe form, might have caused death.
ÔÇ∑Requires inpatient hospitalization or prolongation of an existing hospitalization (except 
scheduled hospitalizations for non-acute, unrelated cause such as an elective surgery)
ÔÇ∑Results in persistent or significant disability/incapacity
ÔÇ∑Is a congenital anomaly/birth defect in the offspring of an exposed subject
ÔÇ∑Important medical events that may not result in death, be life threatening, or require 
hospitalization, may be considered an SAE when, based upon appropriate medical judgment, 
it jeopardizes the subject and may require medical or surgical intervention to prevent one of 
the outcomes listed in this definition.
ÔÇ∑Any death occurring within 30 days of the subject receiving study drug, regardless of the 
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 34 of 43Protocol STUDY-20-01329
subject having discontinued from the protocol, must be reported as an SAE.
Other important medical events may also be considered an SAE when, based on appropriate 
medical judgment, they jeopardize the subject or require intervention to prevent one of the 
outcomes listed.
AE/SAE Reporting Procedure 
To Mount Sinai PPHS (IRB)
AEs are reportable to the IRB within 5 business days (SAEs within 24 hours of knowledge of the 
event) when they meet the following definition:
Any ‚Äòharm‚Äô experienced by a subject or other individual that in the opinion of the 
investigator is unexpected AND at least probably related to the research
All AE/SAEs with an onset date after the subject signs consent for study participation must be 
reported to the IRB at the time of annual renewal. Details of the event must include severity, 
relationship to study drug, duration, action taken, and outcome.
All AE/SAEs that are considered related to study drug must be followed to resolution or stabilization if 
improvement is not expected. AE/SAEs that completely resolve and then recur should be recorded as a new 
AE/SAE. AE/SAEs continuing at 30 days post-last dose should have a comment in the source documents by 
the PI that the event has stabilized or is not expected to improve.
11 DISCONTINUATION AND REPLACEMENT OF SUBJECTS
Participants will be exited from the study once a screening determination is made 
(eligible/ineligible) for further DAC studies or once they become lost to follow-up. 
Participants may re-enter the study for re-screening if necessary.
All subjects are free to withdraw from participation at any time, for any reason, specified or 
unspecified, and without prejudice.
Reasonable attempts will be made by the investigator to provide a reason for subject withdrawals. 
The reason for the subject‚Äôs withdrawal from the study will be specified in  the subject‚Äôs source 
documents.
Subjects who withdraw from the study will not be replaced.
12 Withdrawal of Subjects from the Study
A subject may be withdrawn from the study at any time if the subject, the investigator, or the 
Sponsor feels that it is not in the subject‚Äôs best interest to continue.
All subjects are free to withdraw from participation at any time, for any reason, specified or 
unspecified, and without prejudice.
Reasonable attempts will be made by the investigator to provide a reason for subject withdrawals. 
The reason for the subject‚Äôs withdrawal from the study will be specified in
the subject‚Äôs source documents.
13 PROTOCOL VIOLATIONS
A protocol violation occurs when the subject or investigator fails to adhere to significant 
protocol requirements affecting the inclusion, exclusion, subject safety and primary endpoint 
Effective Date: 6/6/2023
End Date:6/5/2024

C o nfi d e nti al 
P a g e 3 5 of 4 3 Pr ot oc ol S T U D Y- 2 0- 0 1 3 2 9 
criteria. Pr ot oc ol vi olati o ns f or t his st u d y i ncl u de, b ut are n ot li mite d t o, t he f oll o wi n g: 
ÔÇ∑Fail ure t o meet i ncl usi o n/e xcl usi o n criteria 
ÔÇ∑Use of a pr o hi bite d c o nc o mita nt me dicati o n 
ÔÇ∑P ositi ve uri ne t o xic ol o g y scree ni n g 
Fail ure t o c o m pl y wit h G o o d Cli nical Practice ( G C P) g ui deli nes will als o res ult i n a 
pr ot oc ol vi olati o n. T he Pri nci pal I n vesti gat or ( PI) will deter mi ne if a pr ot oc ol vi olati o n 
will res ult i n wit h dra wal of a s u bject. 
W he n a pr ot oc ol vi olati o n occ urs, it will be disc usse d wit h t he i n vesti gat or a n d a Pr ot oc ol 
Vi olati o n F or m detaili n g t he vi olati o n will be ge nerate d. T his f or m will be si g ne d b y a S p o ns or 
re prese ntati ve a n d t he I n vesti gat or. A c o p y of t he f or m will be file d i n t he site‚Äôs re g ulat or y bi n der 
a n d i n t he S p o ns or‚Äôs files. 
1 4 D A T A S A F E T Y M O NI T O RI N G 
Safet y a n d data i nf or mati o n will be re vie we d i n a n o n g oi n g matter b y t he st u d y PI at m o nt hl y pr oject meeti n gs. 
T he cli nical trial tea m, le d b y PI Dr. M urr o u g h, will m o nit or f or t he occ urre nce of D L Ts i n real ti me t hr o u g h o ut 
t he st u d y. T he occ urre nce ( Yes/ N o) of a D L T f or e ver y ne wl y e nr olle d partici pa nt will be f or mall y re vie we d 
at eac h of t he wee kl y researc h meeti n gs a n d at t he bi- wee kl y pr oject meeti n gs t hat are atte n de d b y t he lar ger 
i n vesti gati o nal tea m, t o i ncl u de Drs. Ste wart, De Vita, S mit h, a n d G o vi n daraj ul u. Please see t he relate d D at a 
S afet y a n d M o nit ori n g Pl a n  a n d Pr otecti o n of H u m a n S u bjects  d oc u me nts f or details re gar di n g d ose 
escalati o n pr oce d ures f or t he st u d y. 
T he f oll o wi n g i n di vi d uals will lea d t he eff orts of t he data safet y a n d m o nit ori n g c o m mittee: 
M S S M Pri nci p al M o nit or: 
Pri nci p al I nvesti g at or 
L ast N a me: M urr o u g h 
First N a me: J a mes 
Ac a de mic Title: M D, P h. D. 
De p art me nt: Psyc hi atry 
M aili n g A d dress: O ne G ust ave L. Levy Pl ace De p art me nt of Psyc hi atry, B ox 1 2 3 0 Ne w Y ork, Ne w Y ork 1 0 0 2 9 
P h o ne: 2 1 2- 5 8 5- 4 6 4 0 
F ax: 2 1 2- 2 4 1- 3 3 5 4 
E- m ail: j a mes. m urr o u g h @ mss m.e d u 
M S S M A d diti o n al M o nit or: 
Te a m Me m ber 
L ast N a me: A bles 
First N a me: Jessic a 
Ac a de mic Title: Assist a nt Pr ofess or 
De p art me nt: Psyc hi atry a n d Ne ur oscie nce 
M aili n g A d dress: O ne G ust ave L. Levy Pl ace De p art me nt of Psyc hi atry, B ox 1 2 3 0 Ne w Y ork, Ne w Y ork 1 0 0 2 9 
P h o ne: 2 1 2- 2 4 1- 3 3 5 4 
F ax: 2 1 2- 2 4 1- 3 3 5 4 
E- m ail: : j essic a. a bl es @ mss m. e d u 
S afety M o nit or: 
I n de pe n de nt: 
Eff e cti v e D at e: 6/ 6/ 2 0 2 3 
E n d D at e: 6/ 5/ 2 0 2 4 
Confidential
Page 36 of 43Protocol STUDY-20-01329
Last Name: Levy
First Name: Carol
Academic Title: Professor
Department: Endocrinology, Medicine, Diabetes and Bone Disease, Obstetrics, Gynecology and Reproductive 
Science
Mailing Address: 1190 Fifth Avenue, 1st Floor, New York, NY 10029
Phone: (212) 241-3422
Fax: 212-241-3354
E-mail: carol.levy@mssm.edu 
Dr. Murrough is the director of the Depression and Anxiety Center (DAC) and intimately knowledgeable of this 
study. He will be involved in the clinical care of the subjects and will provide oversight of the entire study. He 
has been involved in many studies in DAC.
Dr. Ables is a co-director of DAC and has extensive experience in clinical trials and psychopharmacology in 
mood disorders.
Dr. Levy is a clinical endocrinologist and certified diabetes educator at Icahn School of
Medicine at Mount Sinai, and has volunteered to join us as a Safety Monitor. Dr. Levy is the director of the 
Mount Sinai Diabetes Center and knows T1D very well clinically and in terms of clinical research. In the event 
of a suspected DLT, Dr. Levy along with Drs. Murrough and Ables will review the event and make the formal 
determination of the occurrence of a DLT, which will subsequently inform the CRM and the dose level of the 
next patients treated in the study.
The DSMC will focus on the following items:
ÔÇ∑Study-related adverse events
oWe would like to note that we are also monitoring for adverse events as per our DLT definition (see 
Definition of Dose Limiting Toxicity above). 
ÔÇ∑Cardiovascular effects: Any of the following that occur after administration of study drug will be considered 
a cardiovascular effect if temporally related to administration of the investigational intervention and 
considered at least possibly related to the investigational intervention:
oSymptomatic hypotension, or > 20% decrease in systolic blood pressure (SBP) from pre-dosing and 
an absolute SBP < 90; or 
oSymptomatic hypertension, or > 20% increase in SBP or diastolic blood pressure (DBP) from pre-
dosing and absolute SBP > 170 or DBP > 95;
oNew onset tachycardia (heart rate >100 bpm) and >20% increase from pre-dosing; or symptomatic 
bradycardia (heart rate <60 bpm) and > 20% decrease from pre-dosing.
oSigns and symptoms of cardiac ischemia, defined by acute ischemic changes on ECG with or without 
concomitant symptoms
ÔÇ∑Protocol compliance
ÔÇ∑Dropouts
ÔÇ∑Confidentiality of participants‚Äô information
ÔÇ∑Other study-specific safety information
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 37 of 43Protocol STUDY-20-01329
15 STATISTICAL METHODS AND CONSIDERATIONS
Human data on oral harmine administration are limited and of poor quality, as noted above. Briefly, there is 
only one study that employed oral doses in the range of 20 to 960 mg (Pennes et al., 1957). No subject had any 
adverse visual hallucinations. Some subjects (number uncertain) experienced ‚Äúnausea, vomiting, slow coarse 
spontaneous tremor, ‚Äòwaviness‚Äô of the environment, ‚Äòsinking‚Äô sensations of the body, subjective sense of body 
vibration, and subject numbness accompanied by reduced sensitivity to light touch and pinprick‚Äù. These effects 
were apparently observed only in ‚Äúsome subjects‚Äù and only ‚Äúoccurred with oral doses higher than the threshold 
of 300.0-400.0 mg.‚Äù In addition, the Callaway Ayahuasca study (Callaway et al., 1999) administered harmine 
in the Ayahuasca ‚Äútea‚Äù at the dose of 3.4 mg/kg (range 204-306 mg). Callaway et al. noted that the effects of 
this dose of harmine (along with other ingredients of Ayahuasca) was perceived to be mild. Thus, based on this 
limited data, doses below 200 mg are likely safe, and single oral doses as high as 1000 mg may also be safe 
and free of significant adverse effects For this reason, and an added layer of caution, we have elected to initiate 
dosing at 100 mg which is less than half of the lower dose range in Callaway study. The upper level of dose 
range (1200 mg) is 4-times that of the highest dose of Callaway study.
In terms of selecting the number of doses tested between the established minimum (100 mg) and maximum 
(1200 mg) dose, the most important statistical consideration is whether the doses and dose range under 
investigation are likely to allow an accurate MTD estimate. In general, it is recommended that phase I studies 
contain between 2 and 12 dosing levels (Penel and Kramar, 2013); more levels generally allow for a more 
accurate determination of the MTD. Based primarily on clinical data, together with the available pre-clinical 
safety data, and utilizing established methods for defining the incremental sequence of a range of doses (Le 
Tourneau et al., 2009), our study protocol specifies the following 7 oral harmine dose levels to be tested 
according to the dose escalation model described below: 100 mg, 200 mg, 300 mg, 500 mg, 700 mg, 900 mg 
and 1200 mg.
Our study will employ the continual reassessment method (CRM) to find the MTD of harmine (O'Quigley 
1990). Generally, the CRM starts by selecting a target dose-limiting toxicity rate and a mathematical model 
assumed to govern the relationship between dose and toxicity; the prior dose-toxicity curve. After outcomes 
are observed (i.e., a patient experiences a DLT or not), the dose-toxicity curve is refit incorporating the latest 
outcome. The next dose assigned is that which is most likely to be associated with the target toxicity level (the 
MTD). At every step, the next patient is assigned the dose estimated to be nearest to the MTD. While the ‚Äú3 + 
3‚Äù design is the most commonly employed dose finding design, the CRM is generally accepted by statisticians 
as superior due to two main advantages: (1) the CRM provides a mechanism for stopping at a specified toxicity 
level, whereas the targeted toxicity rate for the MTD from the ‚Äú3 + 3‚Äù design is necessarily in the range of 
16%-33%, and (2) the CRM is more efficient; it can establish the MTD more accurately and precisely from 
fewer patients and it minimizes the number of patients treated at unsafe doses. The CRM is a model-based 
design while that of the 3+3 is a rule-based design.
Our implementation of the CRM is a Bayesian model-based method that will employ a logistic one-parameter 
prior for the model parameter Œ±. We have chosen this model for two principal reasons; its simplicity and 
efficiency. Generally, the one-parameter model is more efficient than two parameter models. That is, it 
requires fewer patients to precisely estimate that aspect of the dose-toxicity curve that is allowed to vary (the 
slope or steepness parameter). This increased efficiency in parameter estimation may come at the cost of a 
slight decrease in the accuracy of depicting the entire dose-toxicity relationship. However, the CRM has 
proven to be robust in choosing an MTD, even if the functional form is moderately incorrect. In large part this 
robustness is due to the fact that the CRM is not concerned with accurately estimating all aspects of the dose-
toxicity curve, but rather the area near the location of the MTD. The Inputs to specify for our model are: target 
toxicity pT as single-parameter (Œ∏) dose-toxicity curve, K for number of doses, R for odds ratio (OR), and Œ± for 
accuracy. If we use a one-parameter logistic model for the dose response curve, we would have a one-
parameter dose response curve where d is the dose: 
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 38 of 43Protocol STUDY-20-01329
ùúë(ùëë,ùõº)= ùëí3+ùõºùëë
1+ùëí3+ùõºùëë
We will assign a prior probability distribution to the model parameters, assigning a prior probability of DLT at 
each dose based on the available data (Legedza, 2001). In order to minimize risk, we will implement a 
common modification to the CRM such that the first patient treated in the study will be treated at the lowest 
available dose (e.g., 100 mg) regardless of the prior distribution (Goodman et al, 1995). The study will end 
when either the maximum number of allowable patients treated per protocol is reached (see below), or it will 
end early in the event that the probability that the next 10 patients to be dosed in the trial will be given the 
same dose level, regardless of DLT outcomes observed exceeds 90% (Zohar and Chevret, 2001).
16 DATA COLLECTION, RETENTION AND MONITORING
16.1 Data Collection Instruments
The Investigator will prepare and maintain adequate and accurate source documents designed to
record all observations and other pertinent data for each subject treated with the study drug.
Study personnel at each site will enter data from source documents and paper Case Report Forms (CRF) 
corresponding to a subject‚Äôs visit into the protocol-specific electronic Case Report Form (eCRF) when the 
information corresponding to that visit is available. Subjects will not be identified by name in the study 
database or on any study documents to be collected by the Sponsor (or designee), but will be identified by a 
unique ID number and initials.
For eCRF data, recorded via REDCap, a date and time stamp tracks data entry and updates to entered data 
and creates an electronic audit trail. For paper CRFs, if corrections are needed the study staff will line 
through the incorrect information, write the correct data, and initial and date the change.
The Investigator is responsible for all information collected on subjects enrolled in this study. All data 
collected during the course of this study must be reviewed and verified for completeness and accuracy by the 
Investigator.
16.2 Data Management Procedures
The data will be entered into a validated database, stored on REDCap.
All data collected will be kept confidential and used for research purposes only. Each participant will be 
assigned a coded identifier that will be used to associate stored data with each participant. Diagnostic 
interviewers will only enter coded identifiers on their notes and forms. The list associating participants‚Äô names 
with coded identifiers will be maintained separately from the data and in a locked file. No participant‚Äôs 
identifying data will be published. All electronic records will be kept confidential to the extent permitted by 
law, stored in a file (including the linking file) on an electronically secure database in the Department of 
Psychiatry at ISMMS maintained by Sinai‚Äôs IT department. 
This database is password protected and only study personnel will be given the password.  A backup of the 
database will be conducted each day and stored on the secure database. Only study personnel will have access 
to the database and backup. The study data will be stored in the database for 2 years after the study is 
completed, allowing for any follow-up analyses. The study personnel will be responsible for the receipt or 
transmission of the data.
The data from the pre-screener is stored in the secure, encrypted online database, Redcap. The database has 
been designed such that no one has access to the subjects‚Äô answers. The study team, including Dr. Murrough 
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 39 of 43Protocol STUDY-20-01329
who is also the PI, only has access to the subject‚Äôs contact information along with an indication as to whether 
or not the participant appears initially eligible based on the parameters set up in the pre-screener.
16.3 Data Quality Control and Reporting
After data have been entered into the study database, a system of computerized data validation checks will be 
implemented and applied to the database on a regular basis. Queries are entered, tracked, and resolved 
through the electronic database, REDCap, directly. The study database will be updated in accordance with the 
resolved queries. All changes to the study database will be documented.
16.4 Archiving of Data
The database is safeguarded against unauthorized access by established security procedures; appropriate backup 
copies of the database and related software files will be maintained.
Databases are backed up by the database administrator in conjunction with any updates or changes to 
the database.
16.5 Availability and Retention of Investigational Records
The Investigator must make study data accessible to the monitor, other authorized representatives of the 
Sponsor (or designee), IRB, and Regulatory Agency (e.g., FDA) inspectors upon request. A file for each 
subject must be maintained that includes the signed Informed Consent, HIPAA Authorization and Assent 
Form and copies of all source documentation related to that subject. The Investigator must ensure the 
reliability and availability of source documents from which the information on the CRF was derived.
All study documents (patient files, signed informed consent forms, copies of CRFs, Study File Notebook, etc.) 
will be kept secured in keeping with Mount Sinai institutional policies.
16.6 Subject Confidentiality
Confidentiality will be protected through the use of participant study ID numbers, generated based on the 
order in which individuals are screened, rather than any identifying information (e.g. names, date of birth). 
Questionnaires, forms and cognitive test results will contain only the subject‚Äôs ID number; no identifying 
information will be included on the data. Diagnostic interviewers will only enter coded identifiers and initials 
on their notes and forms. All health protected information will be kept in locked files or on a secure MSSM 
server that is maintained by IT personnel and designed to house confidential information. The only forms that 
will contain the participants‚Äô names and identifying information will be the consent forms, which will be 
stored in a locked file in the principal investigator‚Äôs locked office. Only the PI and other approved members 
of the DAC research team will have access to the code list which links that participant study ID number to 
health-protected information. The list associating participants‚Äô names with coded identifiers will be 
maintained separately from the data and in a locked file and will be destroyed after study completion.
Participants have the right to withdraw consent at any time by contacting the study principle investigator. At 
that time, samples that have not already been used for research will be promptly withdrawn from storage and 
destroyed by trained laboratory personnel.
Results will be published as group data without the use of characteristics that would identify individual 
subjects. We quote information only by number in conference discussions, scientific reports, or publications, in 
order to maintain anonymity.
17 ADMINISTRATIVE, ETHICAL, REGULATORY CONSIDERATIONS
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 40 of 43Protocol STUDY-20-01329
The study will be conducted according to the Declaration of Helsinki, Protection of Human Volunteers (21 
CFR 50), Institutional Review Boards (21 CFR 56), and Obligations
of Clinical Investigators (21 CFR 312).
To maintain confidentiality, all laboratory specimens, evaluation forms, reports and other records will be 
identified by a coded number and initials only. All study records will be kept in a locked file cabinet and 
code sheets linking a patient‚Äôs name to a patient identification number will be stored separately in another 
locked file cabinet. Clinical information will not be released without written permission of the subject, 
except as necessary for monitoring by the FDA. The Investigator must also comply with all applicable 
privacy regulations (Health Insurance Portability and Accountability Act of 1996).
17.1 Protocol Amendments
Any amendment to the protocol will be written by the Principal Investigator (PI). Protocol amendments can not 
be implemented without prior written IRB approval except as necessary to
eliminate immediate safety hazards to patients. A protocol amendment intended to eliminate an apparent 
immediate hazard to patients may be implemented immediately, provided the IRBs are notified within five 
working days.
17.2 Institutional Review Boards and Independent Ethics Committees
The protocol and consent form will be reviewed and approved by the IRB of each participating center prior 
to study initiation. Serious adverse experiences regardless of causality will be reported to the IRB in 
accordance with the standard operating procedures and policies of the IRB, and the Investigator will keep the 
IRB informed as to the progress of the study. The Investigator will obtain assurance of IRB compliance with 
regulations.
Any documents that the IRB may need to fulfill its responsibilities (such as protocol, protocol amendments, 
Investigator‚Äôs Brochure, consent forms, information concerning patient recruitment, payment or compensation 
procedures, or other pertinent information) will be submitted to the IRB. The IRB written unconditional 
approval of the study protocol and the informed consent form will be in the possession of the Investigator 
before the study is initiated. The IRB unconditional approval statement will be transmitted by the 
Investigator to ISMMS or designee prior to the shipment of study supplies to the site. This approval must 
refer to the study by exact protocol title and number and should identify the documents reviewed and the date 
of review.
Protocol and/or informed consent modifications or changes may not be initiated without prior written IRB 
approval except when necessary to eliminate immediate hazards to the patients or when the change(s) 
involves only logistical or administrative aspects of the study. Such modifications will be submitted to the 
IRB and written verification that the modification was submitted and subsequently approved should be 
obtained.
The IRB must be informed of revisions to other documents originally submitted for review; serious and/or 
unexpected adverse experiences occurring during the study in accordance with the standard operating 
procedures and policies of the IRB; new information that may affect adversely the safety of the patients of 
the conduct of the study; an annual update and/or request for re- approval; and when the study has been 
completed.
17.3 Informed Consent Form
Informed consent will be obtained in accordance with the Declaration of Helsinki, ICH GCP, US Code of 
Federal Regulations for Protection of Human Subjects (21 CFR 50.25[a,b], CFR 50.27, and CFR Part 56, 
Subpart A), the Health Insurance Portability and Accountability Act (HIPAA), and local regulations.
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 41 of 43Protocol STUDY-20-01329
The Investigator will prepare the informed consent form, assent and HIPAA authorization and provide the 
documents to the Sponsor or designee for approval prior to submission to the IRB. The consent form 
generated by the Investigator must be acceptable to the Sponsor and be approved by the IRB. The written 
consent document will embody the elements of informed consent as described in the International 
Conference on Harmonisation and will also comply with local regulations. The Investigator will store an IRB 
-approved copy of the Informed Consent Form at the local study site.
A properly executed, written, informed consent will be obtained from each subject prior to entering the 
subject into the trial. Information should be given in both oral and written form and subjects (or their legally 
authorized representative) must be given ample opportunity to inquire about details of the study. If 
appropriate and required by the local IRB, assent from the subject will     also be obtained. Alternatively, 
Participants will also be given the option to complete the consent remotely, using a telehealth platform 
(VSee, HIPAA-compliant Zoom) or over the phone (using Doximity) and the electronic consent process via 
REDCap survey that will be sent to individuals. If a subject is unable to sign the informed consent form 
(ICF) and the HIPAA authorization, a legal representative may sign for the subject. A copy of the signed 
consent form (and assent) will be given to the subject or the subject‚Äôs legally authorized representative and 
the original will be maintained with the subject‚Äôs records.
17.4 Publications
The publication or presentation of any study results shall comply with all applicable privacy laws, including, but 
not limited to, the Health Insurance Portability and Accountability Act of 1996.
17.5 Investigator Responsibilities
By signing the Agreement of Investigator form, the Investigator agrees to:
1. Conduct the study in accordance with the protocol and only make changes after notifying 
the IRB, except when to protect the safety, rights or welfare of subjects.
2. Personally conduct or supervise the study (or investigation).
3. Ensure that the requirements relating to obtaining informed consent and IRB review and 
approval meet federal guidelines, as stated in ¬ß 21 CFR, parts 50 and 56.
4. Ensure that all associates, colleagues and employees assisting in the conduct of the study are 
informed about their obligations in meeting the above commitments.
5. Maintain adequate and accurate records in accordance with ¬ß21 CFR 312.62 and to make 
those records available for inspection.
6. Ensure that an IRB that complies with the requirements of ¬ß21 CFR part 56 willbe 
responsible for initial and continuing review and approval of the clinical study.
7. Promptly report to the IRB all changes in the research activity and all unanticipated 
problems involving risks to subjects or others (to include amendments and safety reports).
8. Seek IRB approval before any changes are made in the research study, except when 
necessary to eliminate hazards to the patients/subjects.
9. Comply with all other requirements regarding the obligations of clinical investigators and all other 
pertinent requirements listed in ¬ß 21 CFR part 312.
APPENDIX 1. SCHEDULE OF STUDY VISITS
Effective Date: 6/6/2023
End Date:6/5/2024

Confidential
Page 42 of 43Protocol STUDY-20-01329
Screening 
VisitDosing Visit Follow-Up/Exit Visit
Informed Consent x
Pregnancy Test (Urine or Serum) x x x
Urinalysis x x x
Medical History and Clearance x
Urine Toxicology Screening 
(UTOX)x x x
Self-Report Scales x x x
Concomitant Medication Review x
Adverse Experiences Review x x x
Harmine Administration x
Blood Sampling x x
Effective Date: 6/6/2023
End Date:6/5/2024
